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Abstract  
 
The laws governing cannabis are evolving worldwide and associated with changing patterns of 
use.  The main psychoactive drug in cannabis is Δ9-tetrahydrocannabinol (THC), a partial 
agonist at the endocannabinoid CB1 receptor.  Acutely, cannabis and THC produce a range of 
effects on several neurocognitive and pharmacological systems.  These include effects on 
executive, emotional, reward and memory processing via direct interactions with the 
endocannabinoid system and indirect effects on the glutamatergic, GABAergic and 
dopaminergic systems.  Cannabidiol, a non-intoxicating cannabinoid found in some forms of 
cannabis, may offset some of these acute effects. Heavy repeated cannabis use, particularly 
during adolescence, has been associated with adverse effects on these systems, which increase 
the risk of mental illnesses including addiction and psychosis.  Here, we provide a 
comprehensive state of the art review on the acute and chronic neuropsychopharmacology of 
cannabis by synthesizing the available neuroimaging research in humans. We describe the effects 
of drug exposure during development, implications for understanding psychosis and cannabis use 
disorder, and methodological considerations.  Greater understanding of the precise mechanisms 
underlying the effects of cannabis may also give rise to new treatment targets.  
 
Keywords: Addiction; Cannabis; Cognition, Development, Neuroimaging, Psychosis. 
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Abbreviations 
 
ACC = anterior cingulate cortex 
ASL = arterial spin labelling 
BOLD = blood-oxygen-level dependent 
CBD = cannabidiol 
CBF = cerebral blood flow 
CB1R = endocannabinoid type 1 receptor 
CT = computed tomography 
D2R = dopamine type 2 receptor 
DLPFC = dorsolateral prefrontal cortex 
DTI = diffusion tensor imaging 
EEG = electroencephalography 
OFC = orbitofrontal cortex 
FDG = fludeoxyglucose 
fMRI = functional magnetic resonance imaging 
GABA = γ-aminobutyric acid 
MID = monetary incentive delay 
MRI = magnetic resonance imaging 
MRS = magnetic resonance spectroscopy 
NAA = N-acetylaspartate 
NAc = nucleus accumbens 
PCC = posterior cingulate cortex 
PET = positron emission tomography 
PFC = prefrontal cortex 
THC = Δ9-tetrahydrocannabinol 
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1. Introduction 
Cannabis is one of the most widely used recreational drugs in the world (UNODC, 2018). 
The past year prevalence of cannabis use disorders in the United States has been estimated at 
2.9%, or 30.6% among past-year users (Hasin et al., 2015). There has been concern over the link 
between cannabis use and psychiatric illness since the 1960s (Advisory Committee on Drug 
Dependence, 1969; Kolansky & Moore, 1972; Tennant & Groesbeck, 1972), which has 
intensified following a series of large scale epidemiological studies (Andreasson et al. 1987; 
Murray et al., 2007) and wide public debate. A changing legal landscape for the drug has been 
associated with increasing usage and reductions in the perception of harm (Cerdá et al., 2017). 
Acute intoxication and chronic heavy use of cannabis have been associated with a range of 
effects. The potential long-term deleterious effects of particular concern are when heavy 
cannabis use occurs during adolescence, a key developmental period for the brain (Bossong & 
Niesink, 2010). Positive subjective acute effects described as the ‘high’ include euphoria, 
relaxation and sensory intensification (Green et al., 2003). Adverse acute effects include anxiety, 
paranoia, impaired psychomotor performance and cognitive dysfunction (Broyd et al., 2016; 
Curran et al., 2016). Chronic heavy use of the drug is associated with increased risk of 
dependence, psychosis and cognitive impairment (Broyd et al., 2016; Curran et al., 2016; 
Marconi et al., 2016). However, two large meta-analyses suggest that the adverse effects of 
chronic cannabis use on cognition may improve following abstinence (Schreiner & Dunn, 2012; 
Scott et al., 2018). 
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The main psychoactive substance in cannabis is Δ9-tetrahydrocannabinol (THC) (Wachtel 
et al., 2002) which was first isolated from hashish in 1964 by Gaoni and Mechloulam.  THC is 
gaining interest for its broad therapeutic potential. This includes putative anti-epileptic properties 
(Friedman & Devinsky, 2015), analgesic properties in neuropathic and chronic pain (Abrams et 
al., 2007; Mucke et al., 2018; Narang et al., 2008; Svendsen et al., 2004; Wilsey et al., 2008), 
anti-emetic properties in cancer (Davis, 2016; Smith et al., 2015a), and anti-spastic properties in 
stroke and multiple sclerosis (Collin et al., 2007; Marinelli et al., 2017). THC was originally 
described as an agonist of endocannabinoid CB1 receptors (CB1R) (Felder et al. 1992), however, 
there is growing evidence of partial agonist properties at this site from both in vitro (Breivogel & 
Childers, 2000; Govaerts et al., 2004; Kelley & Thayer, 2004; Petitet et al., 1998; Shen & 
Thayer, 1999; Sim et al., 1996) and in vivo (Paronis et al., 2012) studies. The CB1R is a 
widespread G protein-coupled receptor (Pertwee, 2008) found at high concentrations in key brain 
regions associated with reward, emotional and cognitive processing including the neocortex 
(particularly frontal and limbic areas), hippocampus, amygdala, cerebellum, thalamus and basal 
ganglia (see Figure 1) (Glass et al., 1997). THC alters signalling of endocannabinoid transmitters 
such as 2-arachidonoylglycerol and anandamide. These ligands are released endogenously by 
neurons and act on CB1Rs in adjacent γ-aminobutyric acid (GABA)-ergic and glutamatergic 
nerve terminals resulting in retrograde signalling (see Figure 2) (Bloomfield et al., 2016; Castillo 
et al., 2012). THC also demonstrates partial agonist properties in vitro at the CB2 receptor, but 
with lower efficacy than at CB1R. (Pertwee, 2008). As THC has a number of double bonds and 
stereoisomers, this review focuses on the main THC isomer found in cannabis, (−)-trans-Δ9-
tetrahydrocannabinol, which is also referred to in some older studies by its alternative name Δ1-
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tetrahydrocannabinol and as a pharmaceutical preparation using the International Non-
Proprietary Name dronabinol. 
 
The cannabis plant synthesises at least 143 other cannabinoids in addition to THC (Hanuš 
et al. 2016) such as cannabidiol (CBD). With its excellent safety and tolerability profile and lack 
of intoxicating effects, CBD has generated significant interest as a novel treatment for psychosis, 
(Leweke et al., 2012; McGuire et al., 2017) epilepsy (Devinsky et al., 2017; Devinsky et al., 
2018), anxiety disorders (Bergamaschi et al., 2011; Crippa et al., 2004) and addictions 
(Hindocha et al., 2018a; Morgan et al., 2013; Ren et al., 2009). When administered alone, CBD 
has minimal activity at CB1Rs, but it can inhibit the effects of cannabinoid agonists by acting as 
a negative allosteric modulator of CB1Rs (Laprairie et al., 2015). Moreover, CBD can inhibit the 
reuptake and hydrolysis of the endocannabinoid anandamide (Bisogno et al., 2001). CBD has 
many additional targets within and beyond the endocannabinoid system, including activation of 
5-HT1A receptors, α1-adrenoceptors and μ-opioid receptors (for a review see Pertwee, 2008). 
Whilst a balance of THC and CBD is typically found in hashish or resin products produced by 
landrace crops, cannabis plants are increasingly selected to produce THC only (Potter et al. 
2008). The acute harms of THC are dose-dependent (Curran et al., 2002; D'Souza et al., 2004) 
and may be offset by CBD (Bhattacharyya et al., 2010; Englund et al., 2013; Hindocha et al., 
2015; Morgan et al., 2010). THC levels and the THC:CBD ratio in cannabis have risen 
considerably in the USA and Europe in the last two decades (ElSohly et al., 2016; Pijlman et al., 
2005; Potter et al., 2018; Zamengo et al., 2015), which may increase the harms from repeated 
use (Di Forti et al., 2015; Freeman & Winstock, 2015; Freeman et al., 2018b; Schoeler et al., 
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2016). In this article, we refer to cannabis containing THC only or with unknown quantities of 
CBD as ‘cannabis’, and we explicitly state when cannabis contains significant levels of CBD. 
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Figure 1:  The distribution of CB1Rs across the human brain.  
 
 
 
These axial (left), coronal (middle) and sagittal (right) views schematically depict regions of medium and high 
endocannabinoid type 1 receptor (CB1R) concentration. This was extrapolated from mean labelling densities as 
described by Glass et al. (1997). [
3
H]CPP55,940 binding >80 fmol/mg was defined as high and 40-80 fmol/mg was 
defined as medium. Regions with high CB1R concentration include (in alphabetical order): amygdala (not in view), 
cerebellum, cingulate gyrus, dorsal motor nucleus of the vagus, entorhinal cortex, globus pallidus, hippocampal 
formation, middle frontal gyrus, substantia nigra, and Wernicke’s area. Regions with medium CB1R concentration 
include (in alphabetical order): auditory cortex (right), caudate nucleus, mediodorsal nucleus of the thalamus, motor 
cortex, occipitotemporal gyrus, putamen, somatosensory cortex, and visual cortex. Montreal Neurological Institute 
coordinates (x,y,z) are shown above. 
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Figure 2: THC and retrograde endocannabinoid signalling at the synaptic cleft 
 
 
 
 
The cannabinoids 2-arachidonoylglycerol and anandamide are produced endogenously by neurons and act at 
endocannabinoid type 1 receptors (CB1Rs) on adjacent synaptic terminals. CB1R activity leads to retrograde 
suppression of excitation in glutamatergic nerve terminals and retrograde suppression of inhibition in GABAergic 
nerve terminals. Δ9-tetrahydrocannabinol (THC) disrupts this signalling process.  
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  Cannabis and THC can induce transient positive psychotic symptoms in healthy 
individuals (Bhattacharyya et al., 2010; D'Souza et al., 2004; Moreau, 1845; Morrison & Stone, 
2011; Morrison et al., 2009; Morrison et al., 2011). Increased sensitivity to the acute 
psychotogenic effects of cannabis has been found in people with higher schizotypal personality 
traits (Mason et al., 2009) and those with genetic vulnerability (Morgan et al. 2016). This 
increased sensitivity also has been shown to be a predictor of subsequent psychotic disorders 
(Arendt et al., 2005). THC can also elicit schizophreniform negative symptoms which are 
distinct from sedation (Morrison & Stone, 2011). There is consistent epidemiological evidence 
that the drug is a risk factor for schizophreniform psychotic disorders (Di Forti et al., 2015), 
exhibiting dose-dependence (Gage et al., 2016; Marconi et al., 2016; Moore et al., 2007) and 
dose-duration effects (Di Forti et al., 2009).  Even in cannabis users who do not have frank 
schizophrenia, drug use is associated with increased paranoia; (Freeman et al., 2015; Freeman et 
al., 2013) a cardinal symptom of the illness. The available evidence indicates that cannabis 
causes psychosis in susceptible individuals (Murray et al., 2007). However, there is some 
evidence to suggest that causal effects of cannabis on risk of psychosis may be smaller than 
reverse causation from psychosis risk to cannabis use (Gage et al., 2016; Pasman et al., 2018).  
  
Studies in non-human animals show that THC produces morphological changes in brain 
regions with high CB1R expression including the hippocampus (Chan et al., 1998), amygdala 
(Heath et al. 1980) and cortex (Downer et al. 2001). These include reductions in synapses (Heath 
et al., 1980), cell body size (Scallet et al., 1987) and dendritic length (Landfield et al., 1988). 
Additionally, THC and cannabis produce complex effects on neuropharmacology including the 
dopaminergic system (Bloomfield et al., 2016). Alterations in brain structure and function have 
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also been found in human cannabis users, particularly in CB1R-rich areas of the brain that 
support executive, memory and emotional processing (Lorenzetti et al., 2016b; Yucel et al., 
2007). 
 
Heavy cannabis use has been associated with a range of neurocognitive effects of 
relevance to mental illness, which may persist after acute intoxication (Broyd et al., 2016; 
Curran et al., 2016; Volkow et al., 2016).  These include negative effects on attention (Crane et 
al., 2013), executive function (Crean et al., 2011), learning (Crane et al., 2013), memory (Jager 
et al., 2010), psychotic experiences (D'Souza et al., 2004; Fletcher & Honey, 2006), anhedonia 
and anxiety (Dorard et al., 2008). These deficits may be reversible as a meta-analysis of 
neurocognitive performance after at least 25 days of abstinence from cannabis found no evidence 
of impairment (Schreiner & Dunn, 2012). An additional meta-analysis of 69 studies found that 
cognitive impairments in frequent users were of a small effect size, and found no evidence for 
impairment after more than 72 hours of abstinence (Scott et al., 2018). 
 
It is thus timely to review the human imaging literature on the neuropsychopharmacology 
of cannabis. We build upon and extend recent review articles (Blest-Hopley et al., 2018; 
Lorenzetti et al., 2016a; Weinstein et al., 2016; Yanes et al., 2018) by incorporating multiple 
structural, functional, and pharmacological neuroimaging modalities with a focus on both the 
adolescent and adult brain to present a comprehensive overview of the 
neuropsychopharmacology of cannabis. We will begin by describing the effects of acute 
pharmacological challenge of either cannabis or THC before considering neuroimaging studies 
of heavy cannabis users.  As our focus is on cannabis we will omit imaging studies of synthetic 
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cannabinoids (sometimes referred to collectively as “spice”).  We will give additional 
consideration to the neuropharmacology of cannabis during development because CB1R 
expression peaks during the foetal period and adolescence (Jacobus & Tapert, 2014), key periods 
associated with neuroanatomical re-modelling (Bossong & Niesink, 2010; Raznahan et al., 
2014). This is because of potential harms associated with maternal cannabis exposure during 
gestation and breast-feeding, and because adolescence and young adulthood is the period of peak 
cannabis use (Copeland et al., 2013), and may be a particularly vulnerable period to the acute 
effects of cannabinoids (Curran et al., 2016).  Given the public health implications, we will 
synthesise the literature on implications for understanding psychosis and cannabis use disorder 
before describing important methodological considerations.  
 
2. Methodology 
 
For this narrative review, a series of searches of the electronic databases PubMed, 
Medline, and Ovid were conducted to identify relevant studies between 1966 and (19
th
 
September) 2018. Google Scholar updates were used for search terms ‘cannabis’, ‘marijuana’, 
‘THC’, and key papers were manually searched to identify further studies. The following search 
terms were used: ‘cannabis’; ‘THC’; ‘Δ9-tetrahydrocannabinol’; ‘Δ1-tetrahydrocannabinol’; 
‘dronabinol’; ‘tetrahydrocannabinol’; ‘marijuana’; ‘endocannabinoid’; ‘cannabinoid’; ‘CB1’; 
‘glutamate’; ‘glutamatergic’; ‘GABA’; ‘gamma-aminobutyric acid’; ‘dopamine’; 
‘dopaminergic’; ‘N-acetylaspartate’; ‘neuropsychopharmacology’; ‘pharmacology’; ‘functional 
magnetic resonance imaging’; ‘fMRI’; ‘blood oxygen level dependent’; ‘BOLD’; ‘diffusion 
tensor tractography’; ‘DTT’; ‘diffusion tensor imaging’; ‘DTI’; ‘spectroscopy’; 
‘electroencephalography’; ‘EEG’; ‘computed tomography’; ‘CT’; ‘single photon emission 
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tomography’; ‘SPECT’; ‘positron emission tomography’; ‘PET’; ‘neuroimaging’; ‘brain 
imaging’; ‘brain structure’; ‘cerebral blood flow’; ‘cerebral perfusion’; ‘brain volume’; 
‘attention’; ‘salience’; ‘awareness’; ‘response inhibition’; ‘reward’; ‘executive function’; 
‘learning’; ‘memory’; ‘recall’; ‘amnesia’; ‘emotion’; ‘affect’; ‘decision’; ‘cognition’; ‘cognitive 
impairment’; ‘brain activity’; ‘psychomotor’; ‘movement’; ‘’brain function; ‘psychosis’; 
‘schizophrenia’; ‘psychotomimetic’; ‘adolescent’; ‘young adult’; ‘brain maturation’; ‘brain 
development’; ‘neurodevelopment’. There was no language restriction. Articles were only 
included if they were directly related to the topic and employed a quantitative research design.  
 
3. The acute effects of cannabis and THC 
  
Cerebral Blood Flow and Metabolism 
  
The first neuroimaging studies using acute cannabinoid challenge were a series of 
experiments using 
133
Xe inhalation cerebral blood flow tomography. Acutely, THC alters global 
and regional cerebral blood flow (CBF) (Mathew et al., 1989; Mathew et al. 1992a; Mathew et 
al. 1992b; Mathew & Wilson, 1993). Nearly every study using H2[
15
O]- positron emission 
tomography (PET) found THC-induced increases in CBF in the frontal cortex, insula and 
cingulate gyrus (Mathew et al., 1997; Mathew et al., 1998; Mathew et al., 1999; Mathew et al., 
2002; O'Leary et al., 2000; O'Leary et al., 2002; O'leary et al., 2007). In contrast, one hour after 
smoking a ‘joint’, decreases in cortical CBF were observed. Importantly, these pioneering 
studies found relationships between cannabinoid-induced increases in CBF and subjective 
intoxication, dissociation, depersonalisation and confusion (Mathew et al., 1992b; Mathew et al., 
1993). Subsequently, magnetic resonance imaging (MRI) measures of CBF such as arterial spin 
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labelling (ASL) have corroborated the PET findings (van Hell et al., 2011). In terms of 
metabolism, using [
18
F]-deoxyglucose (FDG) PET, Volkow et al. (1996) demonstrated that acute 
THC increased metabolism in the basal ganglia and the orbitofrontal cortex (OFC) and prefrontal 
cortex (PFC). Taken together, these studies indicate that acute THC causes region-specific 
increases in CBF and metabolism, particularly in frontal regions. 
  
Resting state networks 
  
In healthy volunteers, THC inhalation (2 mg or 6 mg) vs. placebo, increased functional 
connectivity in the sensorimotor network and dorsal visual streams alongside reduced 
connectivity in the right hemisphere between the superior frontal pole, middle and inferior 
frontal gyri and dorsolateral prefrontal cortex (DLPFC) (Klumpers et al., 2012). However, that 
study was compromised by a 41% drop-out rate during THC challenge, particularly in women.  
Post-hoc analysis suggested this may have been due to higher peak plasma THC concentrations 
in women compared to men. Another study found no effects of 10 mg oral THC on frontostriatal 
connectivity in healthy volunteers (Grimm, et al., 2018). However, this may have been 
attributable to low concentrations of THC during scanning. In the same study, the authors found 
that CBD (600 mg oral) increased frontostriatal connectivity.  THC-induced changes in 
functional connectivity have also been observed in regular drug users, whereby THC (450 
micrograms/kg inhaled) resulted in reduced functional connectivity between the nucleus 
accumbens (NAc) and the PFC, limbic lobe, striatum and thalamus in a manner similar to acute 
cocaine (300 mg oral; Ramaekers et al., 2016). Importantly, those results were moderated by 
dopamine beta-hydroxylase enzyme genotype, with CC/TT (low activity) carriers showing 
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greatest reduction in functional connectivity. Moreover, sub-cortical functional connectivity was 
inversely related to impulsivity scores on the matching familiar figures test, indicating that those 
who experienced greater reductions in functional connectivity following THC showed increased 
impulsivity at the behavioural level.  
  
Attentional processing 
          
Acute cannabis inhalation reduces CBF during the performance of focused attention tasks 
(dichotic listening and auditory reaction time tasks) in visual and auditory cortices (O'Leary et 
al., 2002; O'leary et al., 2007), and brain regions that are part of the attentional network (parietal 
lobe, frontal lobe, and thalamus) (O'Leary, et al., 2002). Using a visual oddball task, 10mg oral 
THC increased activation in the right PFC, attenuated activation in the right caudate and 
increased response latency to oddball stimuli (Bhattacharyya et al., 2012). There was a negative 
relationship between THC-induced caudate hypoactivation and both psychotic symptoms and 
effects on response latency.  That study also included a CBD challenge which found opposite 
effects compared to THC alongside hippocampal hyper-activation. Acute inhaled vaporised THC 
(6mg), compared to placebo, resulted in increased false alarms and reduced target detection 
during a continuous performance of sustained attention task (Bossong, et al., 2013a). Impaired 
task performance was related to impaired deactivation of default mode regions including the 
posterior cingulate and angular gyrus, without effects on the central executive system.  
  
Response inhibition 
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Using a Go/No-Go task 10mg oral THC increased the blood-oxygen-level dependent 
(BOLD) response in temporal and posterior regions yet attenuated responses in the anterior 
cingulate cortex (ACC) and inferior frontal cortices (Borgwardt et al., 2008). Studies using a 
similar task and dose (Bhattacharyya et al., 2010; Bhattacharyya et al., 2015) found that THC 
attenuated parahippocampal activation and inferior frontal activation, and the latter was inversely 
correlated with the frequency of inhibition errors and severity of psychotic symptoms. 
Vulnerability to inhibition errors is partially dependent on AKT1 genotype as A allele carriers of 
the rs1130233 single nucleotide polymorphism had increased inhibition errors compared to G 
allele homozygotes (Bhattacharyya et al., 2014). This may be clinically important as people who 
are more susceptible to the psychotogenic effects of cannabis are more likely to make inhibition 
errors than those who do not have a psychotogenic response (Atakan et al., 2013) and AKT1 
genotype modulates risk of psychosis from cannabis use (Di Forti et al., 2012) and the acute 
psychotogenic effects of cannabis (Morgan, et al., 2016). 
  
Reward function 
  
Monetary reward tasks have been used to probe reward processing.  Using the Monetary 
Incentive Delay (MID) task, inhaled THC (6mg using a vaporizer) induced a widespread 
attenuation of BOLD response to feedback in reward trials in the inferior parietal and temporal 
gyrus bilaterally, posterior and anterior cingulate, middle orbitofrontal gyrus, and right superior 
frontal gyrus (van Hell et al., 2012).  An additional study by the same laboratory compared the 
effects of inhaled 6mg THC versus placebo in 11 healthy controls and 10 people with nicotine 
dependence (Jansma et al., 2013). THC did not influence response to reward feedback in healthy 
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controls, consistent with the study by van Hell and colleagues (van Hell et al., 2012). However, 
THC reduced the NAc response to reward anticipation in nicotine-dependent participants. There 
is also evidence that cannabis influences other (non-monetary) rewards, such as music.  Inhaled 
cannabis (containing THC but not CBD) dampened participants’ response to music reward in 
auditory cortex bilaterally and the right hemisphere hippocampus, parahippocampal gyrus, 
amygdala and ventral striatum (Freeman et al., 2018a). These effects were offset when 
participants were administered cannabis containing CBD as well as THC.  This suggests that 
THC dampens the effects of consummatory rewards (consistent with van Hell et al., 2012), 
whereas CBD may offset this effect.  
 
Learning and memory 
 
There is a high density of CB1Rs in the hippocampus and PFC (Curran et al., 2016) and 
disruptions of learning and memory are some of the most widely replicated acute effects of 
cannabis (Broyd et al., 2016). Using a Sternberg item recognition paradigm with four conditions 
(2–5 digits), THC caused a dose-dependent increase in reaction times and decrease in 
performance accuracy as a function of memory load (Böcker et al., 2010). This decline of 
working memory accuracy was significantly correlated with THC-induced decreases in resting 
state electroencephalography (EEG) theta power measured after task performance (Böcker et al., 
2010). Bossong et al. (2012a) studied the acute effects of THC inhalation (6 mg) on performance 
of a parametric Sternberg item recognition paradigm with five difficulty levels. During the 
placebo condition, brain activity increased linearly with rising working memory load. THC 
administration enhanced activity for low working memory loads, and reduced the linear 
relationship between working memory load and activity in a network of working memory related 
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brain regions, and in left DLPFC, inferior temporal gyrus, inferior parietal gyrus, and cerebellum 
in particular. In addition, performance accuracy after THC was only reduced for moderately high 
working memory loads. These results suggest that participants exhibit enhanced brain activity 
during working memory tasks that they perform at normal level, indicating inefficient working 
memory function after THC administration (Bossong et al., 2012a). Whilst no behavioural 
differences in recall tasks were observed during a verbal paired associative learning task, oral 
10mg THC (vs. placebo) abolished the normal decrement in parahippocampal activation during 
encoding and attenuated ventrostriatal activation during word retrieval (Bhattacharyya et al., 
2009).  Under placebo conditions participants sensitive to the psychotogenic effects of cannabis 
had higher hippocampal activation during verbal encoding compared to participants without a 
psychotogenic response (Bhattacharyya et al., 2018). In keeping with these findings, while THC 
(6 mg inhaled) reduced activity during encoding in the right insula, the right inferior frontal 
gyrus, and the left middle occipital gyrus during performance of a pictorial associative memory 
task, activity during recall was significantly increased in a network of recall-related brain 
regions, with most prominent effects in the cuneus and precuneus. Although administration of 
THC did not affect performance accuracy, better performance was associated with lower recall 
activity during the placebo but not the THC condition (Bossong et al., 2012b).  Using a 
Pavlovian fear extinction paradigm, pre-extinction acute THC (compared to placebo) caused 
increased ventromedial PFC and hippocampal activation to a previously extinguished 
conditioned stimulus during extinction memory recall (Rabinak et al., 2014). When users were 
administered oral THC (17mg) challenge while undergoing [
18
F]FDG PET and performing a 
virtual reality maze (Weinstein et al., 2008) acute THC caused more navigation errors and this 
was associated with increased metabolism in the frontal and anterior cingulate cortices (regions 
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associated with motor coordination and attention), and reduced metabolism in areas that are 
related to visual integration of motion.  Taken together these studies suggest that even when 
THC dose is not sufficiently high to result in deleterious effects on behavioural performance, 
increased brain activity has been reported across a range of tasks. One common interpretation of 
such results is that THC reduces the neural ‘efficiency’ of learning and memory processes. 
However, the term ‘efficiency’ in this context is problematic (Poldrack, 2015), and these results 
are consistent with a number of alternative explanations.  
  
Emotional processing 
  
There is a high density of cannabinoid receptors in key areas of the brain involved in 
processing emotional stimuli, such as the amygdala and ACC (Herkenham et al., 1991; Katona et 
al., 2001). Moreover, the availability of CB1Rs receptor in the amygdala, assessed with PET 
imaging, seems to mediate the salience of threatening cues; particularly relevant to anxiety and 
salience processing in psychosis (Pietrzak et al., 2014).  
 
Acute inhaled THC (8mg) impaired recognition of emotional faces at the behavioural 
level (Hindocha et al., 2015). Some studies also suggest that the effects of THC on emotional 
processing are valence specific. Using an emotional matching task, inhaled THC (6mg) impaired 
task performance, measured as mean percentage of correctly identified targets, for matching 
emotional faces with negative, but not positive emotional content (Bossong et al., 2013b). In a 
network of brain regions including amygdala, orbitofrontal gyrus, hippocampus and PFC, neural 
activity was reduced while processing stimuli with a negative emotional content and increased 
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during processing of positive stimuli. Using a similar paradigm, Phan et al. (2008) found that 
7.5mg oral THC reduced amygdala reactivity to social signals of threat (angry and fearful faces) 
with no effect on response times, accuracy or subjective anxiety. This suggests that THC may 
play an anxiolytic role in fear behaviours. In a further analysis of the same data set, Gorka et al. 
(2015) showed that THC reduced functional coupling between the basolateral amygdala and 
superficial amygdala with the rostral ACC and medial PFC, respectively. It is possible that THC-
induced hypoconnectivity between the amygdala and cortex underlies the dissociation between 
subjective and behavioural responses.   
  
Two papers analysed data from a study using a gender discrimination task involving 
looking at mildly fearful and intensely fearful faces after 10mg oral THC in 15 healthy male 
volunteers. In the first paper, Fusar-Poli et al. (2009) found that THC increased skin conductance 
response amplitudes to fearful faces relative to both CBD and placebo. Also, THC primarily 
modulated activity in the frontal and parietal cortex to the faces, with no difference in the 
amygdala. Specifically, during processing of mildly fearful faces, THC increased activation in 
the right inferior parietal lobule, and decreased activation in the left medial frontal gyrus. 
Activity in the left precuneus and primary sensorimotor cortex increased during processing 
related to intensely fearful faces, with decreased activation seen in the middle frontal gyrus and 
posterior cingulate gyrus. During the processing of fearful faces (mild plus intense) THC 
decreased activation in the right inferior frontal gyrus, right superior temporal gyrus, and left 
medial frontal gyrus, and increased activation in the left precuneus. This suggests that THC-
induced anxiogenesis may not be mediated through amygdala reactivity. In a subsequent paper, 
Bhattacharyya et al. (2010) investigated areas where CBD and THC had opposite effects, which 
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included the cerebellum, fusiform gyrus, lingual gyrus, lateral PFC and the amygdala. These 
opposite effects of THC and CBD are consistent with evidence that THC and CBD have opposite 
effects on emotional face recognition at the behavioural level, and that CBD can protect against 
THC-induced impairments in face recognition (Hindocha, et al., 2015). 
 
Further evidence of THC-induced increases in amygdalar response during implicit and 
explicit emotional processing comes from research using the International Affective Picture 
System (Gorka, et al., 2016). Compared to placebo, 7.5mg THC resulted in increased left 
amygdala activation during the passive experience of unpleasant images compared to looking at 
neutral images. This suggests that amygdala activation to negative stimuli is greater after a THC 
challenge. Furthermore, the THC group exhibited greater left amygdala activation, and less 
amygdala-DLPFC coupling during cognitive reappraisal, in comparison to placebo.  
 
These studies indicate that THC has complex effects on BOLD responses to fearful faces, 
involving a pattern of increased and decreased activation in both frontal and parietal areas. 
Although both studies (Bossong et al., 2013b; Fusar-Poli et al., 2009) found lower THC-induced 
brain activity in prefrontal and temporal areas during processing of threatening stimuli, 
differences in the results (Bossong et al., 2013b; Fusar-Poli et al., 2009; Phan et al., 2008) may 
reflect differences in the functional magnetic resonance imaging (fMRI) task. In contrast to the 
other two studies, Fusar-Poli et al. (2009) used a gender discrimination task, which did not 
require explicit processing of the emotional content of the stimuli. In a further exploration of this 
fMRI study on emotional processing, Fusar-Poli et al. (2010) did not show any effects of THC 
administration on connectivity between the amygdala and ACC. Nonetheless, all studies suggest 
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a striking difference between the acute effects of THC on processing of emotions and on 
experiencing of emotions. Whereas THC shifts the emotional bias away from fearful stimuli in 
most studies (Bossong et al., 2013b; Fusar-Poli et al., 2009; Phan et al., 2008) its administration 
enhances subjective feelings of anxiety, particularly when high doses are given to less 
experienced participants in a laboratory setting (Crippa et al., 2009; D'Souza et al., 2004; Ilan et 
al., 2005; Karniol et al., 1974; Morrison et al., 2009; Zuardi et al., 1982)  (for a review see 
Crippa et al. (2009)).  
  
The dopaminergic system 
  
PET can directly measure the dopaminergic system using radiolabelled selective 
dopamine receptor antagonists such as [
11
C]-raclopride. Using PET and the dopamine D2/3 
receptor tracer [
11
C]-raclopride in seven healthy volunteers, Bossong et al. (2009) found that 
inhalation of THC (8 mg) induced a moderate but significant reduction in [
11
C]-raclopride 
binding in the ventral striatum and precommissural dorsal putamen (3.4% and 3.9%, 
respectively), which is consistent with an increase in dopamine levels in these regions (Bossong 
et al., 2009). Stokes et al. (2009) scanned thirteen healthy subjects using a similar PET 
methodology, but did not show effects of oral THC administration (10 mg) on [
11
C]-raclopride 
binding, despite an increase in schizophrenia-like symptoms. However, although not statistically 
significant, THC administration caused a radiotracer displacement of 1.6% and 3.2% in the right 
and left ventral striatum, respectively, which is within a similar range to that reported by 
Bossong et al. (Stokes et al., 2009). A pooled re-analysis of these two studies revealed a 
significant reduction in [
11
C]-raclopride binding in the limbic striatum (−3.65%) after THC 
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administration (Bossong et al., 2015). Finally, using single photon emission computerized 
tomography and [
123
I]-iodobenzamide, Barkus et al. (2011) failed to show an effect of 
intravenously administered THC (2.5 mg) on striatal dopamine concentrations in nine healthy 
men. Unfortunately, this study was not conducted at radiotracer equilibrium conditions, thus not 
allowing quantifiable information regarding the effects of the challenge. Collectively, these data 
provide human evidence for a modest increase in striatal dopamine transmission after 
administration of THC compared to other drugs of abuse. 
 
Interactions with γ-aminobutyric acid (GABA) 
  
Using EEG, Radhakrishnan et al. (2015) used pre-treatment with iomazenil, an iodine 
analogue of the benzodiapine receptor competitive antagonist flumazenil, to demonstrate that 
GABA deficits enhance the neuropsychopharmacological effects of intravenous THC 
(1.05mg/kg).  When pre-treated with iomazenil, THC induced significantly greater psychotic 
symptoms, perceptual alterations, subjective distress and a concomitant reduction in THC-
induced P300 amplitude.  This may be clinically important because reductions in P300 amplitude 
have been observed in psychiatric illnesses including schizophrenia (Bramon et al., 2004).  
  
Table 1.1: Neuroimaging studies of the acute effects of THC and cannabis on cerebral blood flow and metabolism, and resting 
state networks. 
Author 
Imag
ing 
Mod
ality 
User 
Group
s 
Grou
p 
Samp
le 
Size 
(n) 
Group Definition Drug Task 
User 
Age 
Mea
n 
(SD) 
Dose 
of 
THC 
Rou
te 
Increase 
 (volume, blood 
flow, activation, 
connectivity) 
Decrease 
(volume, blood 
flow, activation, 
connectivity) 
Task 
Perfor
manc
e (THC 
vs 
comp
arison 
group 
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or 
baseli
ne) 
Acute effects on cerebral blood flow and metabolism 
Mathe
w et al. 
(1989)  
133Xe 
SPEC
T 
O / Fr 
/ C 
17 / 9 
/ 14 
O = No cannabis for 3y; 
Fr = ≥10 joints/week for 
3y; C = unknown 
cannabis history 
Canna
bis 
Resting 
28.3 
(8.3) 
2.20
% 
S 
Frontal, L 
temporal 
(chronic users 
only) 
Baseline global 
CBF (chronic 
users only) 
- 
Mathe
w et al. 
(1992a)  
133Xe 
SPEC
T 
O 20 O = Unclear previous use 
Canna
bis 
Resting 
25.3 
(6.4) 
1.75
% or 
3.55
% 
S 
R Frontal, R 
temporal 
- - 
Mathe
w et al 
(1992a) 
TCD O 10 O = Unclear previous use 
Canna
bis 
Resting 
25.9 
(6) 
3.55
% 
S 
Middle 
Cerebral Artery 
- - 
Mathe
w & 
Wilson 
(1993) 
133Xe 
SPEC
T 
Fr 35 Fr = Unclear previous use 
Canna
bis 
Resting 
21.7 
(8) 
1.75
% or 
3.55
% 
S 
Global CBF, R 
Frontal 
- - 
Volkow 
et al. 
(1996) 
18F-
FDG 
PET 
Fr / O 8 / 8 
Fr = DSM-III criteria for 
cannabis dependence, 
used for >18m, used for 
mean 5.5y, r1-7d/w; O = 
used cannabis <twice/y 
THC Resting 
31 
(6) 
2mg IV 
Basal banglia, 
OFC, PFC 
Cerebellum 
(chronic users) 
- 
Mathe
w et al 
(1997) 
H2
15
0 
PET 
O 32 
O =  mean onset age 15.7 
(M) 17.6 (F) 
THC Resting 
32.5 
(7.6) 
3mg 
or 
5mg 
IV 
Global CBF, 
frontal cortex, 
R insula, R 
cingulate gyrus, 
R subcortical 
regions 
Frontal CBF at 1 
hour. 
- 
Mathe
w et al. 
(1998) 
H2
150 
PET 
Fr 46 
O = mean 147 (SD 165.2) 
joints/y 
THC Resting 
29.9 
(6.5) 
3mg 
or 
5mg 
IV 
ACC, insula, 
cerebellum 
Cerebellum - 
Mathe
w et al. 
(1999) 
H2
150 
PET 
O 59 
O = mean onset age 16.8 
(3.6)y 
THC Resting 
31.8 
(7.5) 
3mg 
or 
5mg 
IV 
Global CBF 
(R>L), R frontal, 
R insula, ACC 
Basal ganglia, 
thalamus, HPC, 
amygdala 
- 
O'Leary H2
150 O 5 O = use <10 times/m for Canna Audito 26.2 20mg S OFC, insula, Auditory cortex No 
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et al. 
(2000) 
PET mean 3.2y bis ry 
Attenti
on 
Task 
(8) temporal poles, 
ACC, 
cerebellum 
signif
icant 
chan
ge 
Mathe
w et al. 
(2002) 
H2
150 
PET 
Fr 47 
Fr = mean 228.3 (SD 
416.8) joints/y, no 
dependence by DSM-III 
criteria 
THC Resting 
32.0 
(8.3) 
3mg 
or 
5mg 
IV 
Global CBF 
(R>L, A>P), R 
insular, R ACC, 
cerebellum 
(5mg only) 
 
- 
O'Leary 
et al. 
(2002) 
H2
15
0 
PET 
O 12 
O = use <10 times/m, 
mean 2.7 times/m 
Canna
bis 
Audito
ry 
Attenti
on 
Task 
30.5 
(8.6) 
20mg S 
MPFC, insula, 
temporal poles, 
ACC, 
cerebellum 
Auditory cortex, 
Visual cortex, 
Attentional 
Network 
(parietal, frontal, 
thalamus) 
No 
signif
icant 
chan
ge 
O'Leary 
et al. 
(2007) 
H2
150 
PET 
O 12 
O = use <10 times/m, 
mean 5.1 times/m, 
duration mean 3.1y 
Canna
bis 
Audito
ry 
Attenti
on 
Task 
23.5 
(4.3) 
20mg S 
OFC, ACC, 
temporal pole, 
insula, 
cerebellum 
Auditory cortex, 
Visual cortex 
No 
signif
icant 
chan
ge 
van 
Hell et 
al. 
(2011) 
ASL 
& 
fMRI 
O 26 
O = mean use 19.0 (SD 
11.2) in last year 
THC Resting 
21.1 
(2.1) 
6mg INH 
ACC, superior 
frontal cortex, 
insula, 
substantia 
nigra, 
cerebellum 
Post-central 
gyrus, occipital 
gyrus 
- 
Acute effects on resting state networks 
Klumpe
rs et al. 
(2012) 
fMRI O 12 
O = >1y of use duration, 
≤1 use/w 
THC Resting 
22 
(2.9) 
2mg 
or 
6mg 
INH 
sensorimotor 
network , 
dorsal-visual 
streams 
R superior 
frontal pole - 
middle and 
inferior frontal 
gyri - PFC 
network 
- 
Ramae
kers et 
al. 
(2016) 
fMRI Fr 122 
Fr = mean use 7y 
duration, mean 44.8 uses 
in last 3m 
THC Resting 
22.8 
(3.7) 
450µ
g/kg 
INH - 
NAc - PFC, limbic 
lobe, striatum, 
thalamus 
- 
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Grimm 
et al. 
(2018) 
fMRI O 16 ≤5 uses in lifetime THC Resting 
Ran
ge 
18-
50 
10mg PO No significant changes - 
ACC = anterior cingulate cortex, ASL = arterial spin labelling, C = control users, CBF = cerebral blood flow, d = day, DSM = Diagnostic & Statistic 
Manual of Mental Disorders, Fr = frequent cannabis users, F = female, fMRI = functional magnetic resonance imaging, HPC = hippocampus, INH 
= inhaled, IV = intravenous, L = left, m = month, M = male, MPFC = medial prefrontal cortex, NAc = nucleus accumbens, O = occasional cannabis 
users, OFC = orbitofrontal cortex, PFC = prefrontal cortex, PO = per os (oral), PET = positron emission tomography, r = range, R = right, S = 
smoked, SD = standard deviation, SPECT = single photon emission computed tomography, TCD = transcranial doppler, THC = Δ9-
tetrahydrocannabinol, VMPFC = ventromedial prefrontal cortex, w = week, y = year. 
 
Table 1.2: Neuroimaging studies of the acute effects of THC and cannabis on cognitive tasks.  
 
Auth
or 
Ima
gin
g 
Mo
dali
ty 
User 
Grou
ps 
Gro
up 
Sam
ple 
Size 
(n) 
Group Definition 
D
r
u
g 
Task 
Use
r 
Age 
Me
an 
(SD) 
Dose 
of 
THC 
R
o
u
t
e 
Increase 
 (volume, blood flow, 
activation, 
connectivity) 
Decrease 
(volume, blood 
flow, activation, 
connectivity) 
Ta
sk 
Pe
rfo
rm
an
ce 
(T
HC 
vs 
co
mp
ari
so
n 
gr
ou
p 
or 
ba
sel
ine
) 
Acute effects on attentional processing 
O'Lea
ry et 
H2
15
0 
O 5 
O = use <10 times/m 
for mean 3.2y 
C
a
Auditory Attention 
Task 
26.2 
(8) 
20mg S 
OFC, insula, 
temporal poles, 
Auditory cortex 
N
o 
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al. 
(2000
) 
PET n
n
a
bi
s 
ACC, cerebellum sig
nif
ica
nt 
ch
an
ge 
O'Lea
ry et 
al. 
(2002
) 
H2
15
0 
PET 
O 12 
O = use <10 times/m, 
mean 2.7 times/m 
C
a
n
n
a
bi
s 
Auditory Attention 
Task 
30.5 
(8.6
) 
20mg S 
MPFC, insula, 
temporal poles, 
ACC, cerebellum 
Auditory cortex, 
Visual cortex, 
Attentional 
Network 
(parietal, frontal, 
thalamus) 
N
o 
sig
nif
ica
nt 
ch
an
ge 
O'Lea
ry et 
al. 
(2007
) 
H2
15
0 
PET 
O 12 
O = use <10 times/m, 
mean 5.1 times/m, 
duration mean 3.1y 
C
a
n
n
a
bi
s 
Auditory Attention 
Task 
23.5 
(4.3
) 
20mg S 
OFC, ACC, temporal 
pole, insula, 
cerebellum 
Auditory cortex, 
Visual cortex 
N
o 
sig
nif
ica
nt 
ch
an
ge 
Bhatt
achar
yya et 
al. 
(2012
) 
fM
RI 
O 15 
O = <15 uses per 
lifetime 
T
H
C 
Visual Oddball task 
26.7 
(5.7
) 
10mg 
P
O 
R PFC R caudate 
↓ 
re
ac
tio
n 
ti
m
e  
Bosso
ng et 
al. 
(2013
fM
RI 
O 20 
O = mean 22.5 (SD 
15.2) uses/last year, 
mean onset age 15.7 
(SD 1.7), mean 7.3 
T
H
C 
Continuous 
Performance Task 
22.9 
(4.9
) 
6mg 
I
N
H 
PCC, angular gyrus - 
↑ 
fal
se 
al
ACCEPTED MANUSCRIPT
AC
CE
PT
ED
 M
AN
US
CR
IPT
 
a) (SD 5.1) years of use ar
m
s, 
↓ 
de
te
ct
ed 
tar
ge
ts 
Acute effects on response inhibition 
Borg
wardt 
et al. 
(2008
) 
fM
RI 
O 15 
O = <15 uses per 
lifetime 
T
H
C 
Go/No-Go 
26.7 
(5.7
) 
10mg 
P
O 
R HPC, R 
parahippocampal 
gyrus, R temporal 
cortex, L PCC 
R ACC, R inferior 
frontal cortex 
N
o 
sig
nif
ica
nt 
ch
an
ge 
Bhatt
achar
yya et 
al. 
(2010
) 
fM
RI 
O 15 
O = <5 uses per 
lifetime 
T
H
C 
Go/No-Go 
26.7 
(5.7
) 
10mg 
P
O 
Parahippocampal 
gyrus, L insula, L 
caudate 
- 
N
o 
sig
nif
ica
nt 
ch
an
ge 
Bhatt
achar
yya et 
al. 
(2015
) 
fM
RI 
O 36 
O = <25 uses per 
lifetime 
T
H
C 
Go/No-Go 
26.0 
(5.5
) 
10mg 
P
O 
- 
L inferior frontal 
cortex 
↑ 
in
hi
bit
io
n 
er
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ro
rs, 
↓ 
in
hi
bit
io
n 
eff
ici
en
cy 
Acute effects on reward function 
van 
Hell 
et al. 
(2012
) 
fM
RI 
O 14 O = ≥4 uses per year 
T
H
C 
Monetary Incentive 
Delay 
21.7 
(2.3
) 
6mg 
I
N
H 
- 
Inferior parietal 
cortex, temporal 
cortex, PCC, ACC, 
OFC, R superior 
frontal cortex 
N
o 
sig
nif
ica
nt 
ch
an
ge 
Jans
ma et 
al. 
(2013
) 
fM
RI 
Nicoti
ne 
Addic
tion 
Group 
/ C 
10 
Nicotine Addiction 
Group = mean 23.5 
(SD 5.8) uses in last y; 
C = mean 22.6 (SD 
3.6) uses in last y 
T
H
C 
Monetary Incentive 
Delay 
25.6 
(2.1
) 
6mg 
I
N
H 
- 
NAc (Nicotine-
Dependent 
Group) 
N
o 
sig
nif
ica
nt 
ch
an
ge 
Free
man 
et al. 
(2018
a) 
fM
RI 
O 16 
O = mean 8.06 (SD 
5.5) uses/m, mean 
8.94 (SD 7.0) years of 
use 
C
a
n
n
a
bi
Musical Reward 
26.2 
(7.3
) 
6% or 
12% 
I
N
H 
- 
Auditory cortex, 
R HPC, R 
parahippocampal 
gurys, R 
amygdala, R 
ventral striatum 
↑ 
W
an
t 
to 
Lis
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s te
n 
to 
M
usi
c, 
↑ 
So
un
d 
Pe
rc
ep
tio
n 
Acute effects on learning and memory 
Wein
stein 
et al. 
(2008
) 
18F-
FD
G 
PET 
Fr 12 
Fr =≥1 use per day, ≥5 
years of use, mean 
age of onset 19y, met 
DSM-IV criteria for 
dependence 
T
H
C 
Virtual Reality Maze 
27 
(7.4
5) 
17mg S Frontal cortex, ACC 
Visual-Motor 
Areas 
↑ 
Hi
tti
ng 
th
e 
w
all
s  
of 
th
e 
m
az
e 
Bhatt
achar
yya et 
al. 
(2009
) 
fM
RI 
O 15 
O = ≤15 uses per 
lifetime 
T
H
C 
Verbal Paired 
Association Task 
26.7 10mg 
P
O 
Parahippocampal 
gyrus 
Ventrostriatum 
N
o 
sig
nif
ica
nt 
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ch
an
ge 
Böck
er et 
al. 
(2010
). 
EEG O 16 
O = r2-9 uses per 
month 
C
a
n
n
a
bi
s 
Memory Search 
Task 
Ran
ge 
18-
45 
29.3
mg, 
49.1
mg, 
or 
69.4
mg 
S - 
Resting state 
theta power 
↑ 
Er
ro
rs, 
↑
Re
ac
tio
n 
ti
m
e 
Bosso
ng et 
al. 
(2012
b) 
fM
RI 
O 14 
O = mean 17.0 (SD 
12.4) uses per year 
T
H
C 
Sternberg Item 
Recognition 
21.6 
(2.1
) 
6mg 
I
N
H 
Network-wide 
increase, cuneus, 
precuneus 
R insula, R 
inferior frontal 
gyrus, L middle 
occipital gyrus 
↓ 
Pe
rf
or
m
an
ce 
ac
cu
ra
cy 
Rabin
ak et 
al. 
(2014
) 
fM
RI 
O  
14 / 
14 
O = <10 uses per 
lifetime 
T
H
C 
Pavlovian Fear 
Extinction 
Ran
ge 
21-
45 
7.5m
g 
P
O 
VMPFC, HPC - 
N
o 
sig
nif
ica
nt 
ch
an
ge 
Bhatt
achar
fM
RI 
O (TP 
/ NP) 
14 / 
22 
O = <25 uses per 
lifetime 
T
H
Verbal Learning Task - 10mg 
P
O 
L HPC (TP group) - 
N
o 
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yya et 
al. 
(2018
) 
C sig
nif
ica
nt 
ch
an
ge 
Acute effects on emotional processing 
Phan 
et al. 
(2008
) 
fM
RI 
O 16 
O = mean 2.0 (SD 2.4) 
uses/m 
T
H
C 
Angry / Fearful Face 
Matching 
20.8 
(2.6
) 
7.5m
g 
P
O 
- Amygdala 
N
o 
sig
nif
ica
nt 
ch
an
ge 
Fusar
-Poli 
et al. 
(2009
) 
fM
RI 
O 15 
O = <15 uses per 
lifetime 
T
H
C 
Gender 
Discimination Task / 
Viewing Fearful 
Faces (Mild / 
Intense) 
26.6 
(5.7
) 
15mg 
P
O 
R parietal lobe, L 
medial frontal 
gyrus (mild) // L 
precuneus, 
sensorimotor 
cortex (intense) 
Middle-frontal 
gyrus, PCC 
(intense) 
↑ 
SC
R 
flu
ct
ua
tio
ns 
Bhatt
achar
yya et 
al. 
(2010
) 
fM
RI 
O 15 
O = <5 uses per 
lifetime 
T
H
C 
Viewing Fearful 
Faces (Mild / 
Intense) 
26.7 
(5.7
) 
10mg 
P
O 
Amygdala 
L 
parahippocampal 
gyrus, R temporal 
cortex, occipital 
cortex 
N
o 
sig
nif
ica
nt 
ch
an
ge 
Bosso
ng et 
al. 
fM
RI 
O 14 
O = mean 20.0 (SD 
9.4) uses/y 
T
H
C 
Happy / Fearful Face 
Matching 
21.5 
(2.5
) 
6mg 
I
N
H 
- 
Amygdala-OFC-
HPC-PFC-parietal 
cortex-occipital 
↓ 
Pe
rf
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(2013
b) 
cortex network or
m
an
ce 
ac
cu
ra
cy 
du
rin
g 
m
at
ch
in
g 
of 
fe
arf
ul 
fa
ce
s 
Gork
a et 
al. 
(2015
) 
fM
RI 
O 16 
O = ≥10 uses per 
lifetime, <1 use/d 
T
H
C 
Angry / Fearful Face 
Matching 
20.8 
(2.6
) 
7.5m
g 
P
O 
- 
Amygdala-rostral 
ACC-MPFC 
network 
N
o 
sig
nif
ica
nt 
ch
an
ge 
Gork
a et 
al. 
(2016
) 
fM
RI 
O 41 
O = <10 uses per 
lifetime 
T
H
C 
Emotion Regulation 
Task (Passive 
experience of 
negative images – 
look, maintain, 
24.9 
(3.8
) 
7.5m
g 
P
O 
Amygdala 
Amygdala-DLPFC 
network 
↓ 
ne
ga
tiv
e 
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reappraise) aff
ec
t 
fol
lo
wi
ng 
re
ap
pr
ais
e 
vs 
m
ai
nt
ai
n 
co
nd
iti
on
, 
↑ 
ne
ga
tiv
e 
aff
ec
t 
fol
lo
wi
ng 
m
ai
ACCEPTED MANUSCRIPT
AC
CE
PT
ED
 M
AN
US
CR
IPT
 
nt
ai
n 
vs 
lo
ok
, 
↓ 
pl
ea
sa
nt 
rat
in
gs 
an
d 
↑ 
ar
ou
sal 
rat
in
gs 
of 
un
pl
ea
sa
nt 
im
ag
es 
ACC = anterior cingulate cortex, C = control users, d = day, DLPFC = dorsolateral prefrontal cortex, DSM = Diagnostic & Statistic Manual of 
Mental Disorders, EEG = electroencephalogram, Fr = frequent cannabis users, F = female, FDG = fludeoxyglucose, fMRI = functional magnetic 
resonance imaging, HPC = hippocampus, INH = inhaled, L = left, m = month, M = male, MPFC = medial prefrontal cortex, NAc = nucleus 
accumbens, NP = transient psychotic symptoms not induced by THC, O = occasional cannabis users, OFC = orbitofrontal cortex, PFC = prefrontal 
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cortex, PO = per os (oral), PET = positron emission tomography, r = range, R = right, S = smoked, SCR = skin conductance response, SD = 
standard deviation, THC = Δ9-tetrahydrocannabinol, TP = transient psychotic symptoms induced by THC, VMPFC = ventromedial prefrontal 
cortex, w = week, y = year. 
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4. The chronic effects of cannabis and THC 
  
Whole brain volume 
  
Early studies used computed tomography (CT) to investigate whether cannabis use was 
associated with structural alterations in the brain and found that cannabis users did not exhibit 
gross atrophic changes (Co et al., 1977; Hannerz & Hindmarsh, 1983; Kuehnle et al., 1977). 
However, early CT suffered from having limited volumetric data from soft tissue.  Since then, no 
study has reported significant differences in whole brain volume between cannabis users and 
controls, although differences have been reported when cortical grey and white matter are 
examined separately (Lorenzetti et al., 2010).  One study (Wilson et al., 2000) found that early 
cannabis exposure was associated with decreased grey matter volume and increased white matter 
volume in early onset users, although this was not replicated by another study (Tzilos et al., 
2005). 
  
Regional brain structure 
  
As per initial CT research, early MRI studies did not find significant structural deficits 
associated with cannabis use (Block et al., 2000a; Jager et al., 2007; Tzilos et al., 2005). 
Subsequently, hippocampal and parahippocampal atrophy have been associated with chronic 
cannabis use (Ashtari et al., 2011; Demirakca et al., 2011; Filbey et al., 2015; Lorenzetti et al., 
2015; Matochik et al., 2005; Yucel et al., 2008). Even in studies that did not find significant 
reductions in users compared to non-users, there was evidence of a negative correlation between 
cannabis exposure and dependence severity with hippocampal volume (Chye et al., 2018; 
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Cousijn et al., 2012). Since the lack of regional effects may be influenced by lateralisation, a 
meta-analysis found that when the left and right hippocampi are combined there was evidence of 
hippocampal reduction (Rocchetti et al., 2013). However, a longitudinal study of hippocampal 
volume in heavy cannabis users (mean age 21 years) compared to non-users (Koenders et al., 
2016; Koenders et al., 2017) did not find cannabis-induced effects at baseline or 39-month 
follow-up using voxel-based and manual tracing approaches. This is consistent with another, 
recent study using voxel-based analysis, which also revealed no structural changes to the 
hippocampal volume in chronic users (Moreno-Alcazar et al., 2018). Nonetheless, 
inconsistencies may be due to dependence and/or specific effects within the hippocampus as 
other recent work has found that volume deficits are most prominent in the cornu ammonis 1-3 
subfields and dentate gyrus in cannabis-dependent users (Chye et al., 2017b). This would tie in 
with previous findings that cannabis use disorder was associated with morphological differences 
within the hippocampus that were related to episodic memory impairments (Smith et al., 2015b). 
Atrophic and dysmorphogenic effects of cannabis on subcortical structures have been extended 
to the amygdala and NAc (Lorenzetti et al., 2015; Yucel et al., 2008), and hypertrophic changes 
have also been described in the basal ganglia of cannabis users (Moreno-Alcazar et al., 2018). In 
terms of cortical regions, heavy cannabis users have abnormal gyrification (type III), reduced 
orbitofrontal volume (Chye et al., 2017a) and reduced right anterior cingulate volume compared 
to non-users, which is influenced by CB1R haplotype variation (Hill et al., 2016). 
  
Structural connectivity 
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One of the three early diffusion tensor imaging studies found evidence of structural 
dysconnectivity in cannabis users (Arnone et al., 2008; Delisi et al., 2006; Gruber & Yurgelun-
Todd, 2005) in the form of reduced mean diffusivity in the prefrontal section of the corpus 
callosum. Chronic cannabis users were later found to also have microstructural dysconnectivity 
in the splenium of the corpus callosum, fornix and commissural fibres (Zalesky et al., 2012). 
Applying graph theory to diffusion tensor imaging and tractography, Kim, et al. (2011) found 
that cannabis users had less efficiently integrated global structural networks alongside altered 
local connectivity in the cingulate. There is also evidence from a small study that reduced frontal 
white matter connectivity was associated with impulsivity in cannabis users (Gruber et al., 
2011), however since impulsivity is a risk factor for drug use it is possible that this pre-dates the 
cannabis use. Nonetheless, other studies have found effects on orbitofrontal connectivity 
whereby structural fractional anisotropy in the forceps minor increased with regular use but then 
decreased following long-term heavy use (Filbey et al., 2014), which would support an effect of 
drug use on structural connectivity.   
  
The first longitudinal evidence for cannabis effects on white matter structure came from 
two studies (Becker et al., 2015; Epstein & Kumra, 2015). Compared to controls, adolescents 
with cannabis use disorder had reduced connectivity in the left inferior longitudinal fasciculus 
(Epstein & Kumra, 2015) while cannabis using young adults had attenuated growth in white 
matter connectivity in several key pathways (Becker et al., 2015).  Importantly, greater cannabis 
consumption was associated with reduced connectivity. These findings were corroborated by a 
large study of 466 adults reporting recreational cannabis use from the Human Connectome 
Project (Orr et al., 2016). Whilst that study did not find group differences between recreational 
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users and non-users, there was a relationship between age of onset of cannabis use and reduction 
in white matter coherence in tracts reported previously including the superior and inferior 
longitudinal fasciculi, and the major and minor forceps of the corpus callosum connecting the 
left and right occipital and frontal lobes, respectively. 
Table 2.1: Neuroimaging studies of the chronic effects of cannabis on brain structure and volume 
Auth
or 
Im
agi
ng 
M
od
ali
ty 
Users / 
Controls (n) 
User age, mean 
(SD) 
unless otherwise stated 
Duration of use (y), 
mean (SD) 
unless otherwise stated 
User onset age 
(y), mean (SD) 
unless otherwise 
stated 
Use frequency in 
joints/cones/uses, 
mean (SD) 
unless otherwise specified 
Increase 
(volume, blood 
flow, activation, 
connectivity) 
Decrease 
(volume, blood 
flow, 
activation, 
connectivity) 
Chronic effects on whole brain structural volume 
Co et 
al. 
(197
7) 
CT 12 / 34 24.1 (-) 6.6 (-) 17.4 (-) 9 (-) /d No significant changes 
Kueh
nle 
et al. 
(197
7) 
CT 19 / 19 23.8 (-) 
Inpatient ward study 
(21d) 
- 34.7 (-) /m No significant changes 
Han
nerz 
et al. 
(198
3)  
CT 12 / 12 26.1 (-) 10.25 (-) - - No significant changes 
Wils
on et 
al. 
(200
0) 
sM
RI 
& 
H2
1
50 
PE
T 
57 / 0 31.3 (7) 
16.9 (6.4) early onset 
[<17yo] males and 
females 13.4 (6.0), 
late onset [>17yo] 
males 13.9 (6.9) and 
females 14.0 (6.6) 
16.8 (3.6) 
240.8 (198.1) early 
onset [<17yo] males 
and females 146.5 
(128.7), late onset 
[>17yo] males 205.6 
(587.0) and females 
128.2 (186.8) /y 
WM volume 
(early-onset 
[<17y] users 
only) 
GM volume, 
whole brain 
(early onset 
users 
[<17yo] only) 
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Bloc
k et 
al. 
(200
0a) 
sM
RI 
18 / 13 22.3 (0.5) 3.9 (0.4) - 18 (2) /w - Ventricles 
Tzilo
s et 
al. 
(200
5) 
sM
RI 
22 / 26 38.1 (6.2) 22.6 (5.7) 16 (4.0) ≧1 /d No significant changes 
Jager 
et al. 
(200
7) 
sM
RI 
20 / 20 24.5 (5.2) - - 322.5 (-) /y No significant changes 
Chronic effects on regional brain structure 
Bloc
k et 
al. 
(200
0a) 
sM
RI 
18 / 13 22.3 (0.5) 3.9 (0.4) - 18 (2)/w No significant changes 
Mat
ochi
k et 
al. 
(200
5) 
sM
RI 
11 / 8 29.7 (4.7) 7.5 (5.5) 15.7 (2.5) 34.7 (17.6)/w 
Precuneus, 
thalamus, 
parahippocam
pal gyrus, pons, 
lentiform 
nucleus, 
fusiform gyrus. 
HPC GM, R 
parahippoca
mpal GM, L 
parietal WM. 
Tzilo
s et 
al. 
(200
5) 
sM
RI 
22 / 26 38.1 (6.2) 22.6 (5.7) 16 (4.0) ≧1/d No significant changes 
Jager 
et al. 
(200
7) 
sM
RI 
20 / 20 24.5 (5.2) - - 322.5 (-) /y No significant changes 
Yüce sM 15 / 16 39.8 (8.9) 39.8 (8.9) 20.1 (6.9) 28 (4.6) /m - HPC, 
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l et 
al. 
(200
8) 
RI amygdala 
Asth
ari et 
al. 
(201
1) 
sM
RI 
14 / 14 19.3 (0.8) - 13.1 (-) 5.8 (-) /d - 
HPC (note 
6.7m 
abstinent 
before trial) 
Dem
irakc
a et 
al. 
(201
1) 
sM
RI 
11 / 13 r19-25 5.4 (-) - - - 
R anterior 
HPC 
Cous
ijn et 
al. 
(201
2) 
sM
RI 
33 / 42 21.3 (2.4) 2.5 (1.9) 18.8 (2.3) 4.9 (1.5) /w 
Anterior 
Cerebellum 
HPC, 
amygdala 
(correlates 
with amount 
of cannabis 
use) 
Filbe
y et 
al. 
(201
4) 
sM
RI 
& 
fM
RI 
48 / 62 28.3 (8.3) 9.8 (8.0) 18.1 (3.4) 11.1 (1.4) /w 
OFC-Forceps 
Minor Network 
Connectivity 
Orbifrontal 
gyrus volume 
Filbe
y et 
al. 
(201
5) 
sM
RI 
1: 36 (cannabis 
users) / 19 
(nicotine users) 
/ 19 (cannabis + 
nicotine users) 
/ 16 (controls) 
24.9 (8.8) 
[cannabis users], 
23.3 (7.3) 
[cannabis + 
nicotine users] 
- - 
80.6 (14.2) / last 90d 
[cannabis users], 82.2 
(11.5) / last 90d 
[cannabis + nicotine 
users] 
- 
HPC 
(cannabis 
users and 
cannabis + 
nicotine 
users) 
Lore
nzett
i et 
al. 
(201
sM
RI 
15 / 16 40 (9) 21 (-) - 28 (3) /m - 
HPC, 
amygdala 
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5) 
Smit
h et 
al. 
(201
5b) 
sM
RI 
10 (cannabis 
users) / 28 
(SZP) / 15 (SZP 
+ cannabis 
users) / 44 
(controls) 
- 2.6 (2.5) 16.7 (-) 80% were daily users 
Altered HPC morphology 
(cannabis users and 
SZP+cannabis users vs. controls) 
Hill 
et al. 
(201
6) 
sM
RI 
34 (split into 
lower / higher 
cannabis use 
groups)/ 54 
27.2 (4.3) [lower 
use], 26.4 (2.8) 
[higher use]  
3.0 (2.9) [lower use], 
6.3 (3.1) [higher use] 
18.1 (4.4) [lower 
use], 18.5 (-) 
[higher use] 
9,167.9 (16,770.9) 
[lower], 17,756.2 
(21,036.3) [higher] 
/lifetime 
- 
R 
anterio
r 
cingulat
e 
(associa
ted 
with 
CNR1 
haploty
pe 
variatio
n) 
Koen
ders 
et al. 
(201
6) 
sM
RI 
20 / 22 
baseline, 39m 
20.5 (2.1) - 14.5 (1.65) 
4.7 (1.6) [baseline], 2.9 
(2.3) [39m] /w 
No significant changes 
Koen
ders 
et al. 
(201
7) 
sM
RI 
20 / 23 
baseline, 39m 
20.6 (2.2) - 16.1 (2.3) 
4.7 (1.6) [baseline], 5.1 
(2.3) [39m follow-up] 
/w 
No significant changes 
Chye 
et al. 
(201
7a) 
sM
RI 
22 ND / 39 D / 
35 controls 
36.2 (11.7) [ND], 
30.3 (10.0) [D] 
- 
17.2 (3.2) [ND], 
16.4 (3.4) [D] 
21.9 (10.3) [ND], 27.4 
(4.5) [D] /m 
- 
CA1, CA2, 
CA3, 
CA4/dentate 
gyrus, total 
HPC GM 
Chye 
et al. 
sM
RI 
140 / 121 28.0 (10.2) - 17.8 (3.3) 334.1 (322.3) /m 
No significant changes in users 
vs control; medial-lateral OFC (D 
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(201
7b) 
vs ND only, F>M) 
Chye 
et al. 
(201
8) 
sM
RI 
1: 140 
[cannabis 
users] / 121 
[controls] 
2: 50 [ND] / 70 
[D] / 106 
[controls] 
3: 41 [ND] / 41 
[D] / 41 
[controls] 
1: 28.0 (10.3) 
[cannabis users], 
2: 27.1 (7.3) 
[ND], 26.7 (9.2) 
[D], 3: 28.6 (10.8) 
[ND], 26.7 (8.5) 
[D] 
- 
1:  17.8 (3.4) 
[cannabis users], 
2: 17.8 (2.7) 
[ND], 17.4 (3.4) 
[D], 3: 17.8 (2.8) 
[ND], 17.5 (2.6) 
[D] 
1: 334.1 (322.3) /m 
[cannabis users], 2: 
229.8 (202.3) /m [ND], 
351.6 (291.0) /m [D], 3: 
235.4 (209.9) /m [ND], 
278.9 (172.8) /m [D] 
 
HPC 
volume 
[D only] 
Mor
eno-
Alcaz
ar et 
al. 
(201
8) 
sM
RI 
14 / 28 (control 
group 1) / 100 
(control group 
2) 
30.1 (5.2) 14.4 (6.7) 17.1 (2.1) 8.4 (3.8) /d 
GM cluster in basal 
ganglia (caudate, 
putamen, pallidum, 
NAc); larger volume 
in putamen, 
pallidum 
- 
 
CA = cornu ammonis, CNR1 = cannabinoid receptor 1 gene, CT = computed tomography, d = day, D = dependent cannabis user, F = female, fMRI 
= functional magnetic resonance imaging, GM = gray matter, HPC = hippocampus, L = left, m = month, M = male, NAc = nucleus accumbens, ND 
= non-dependent cannabis user, OFC = orbitofrontal cortex, PET = positron emission tomography, r = range, R = right, SD = standard deviation, 
sMRI = structural magnetic resonance imaging, SZP = schizophrenia, w = week, WM = white matter, y = year. 
Table 2.2: Neuroimaging studies of the chronic effects of cannabis on structural connectivity 
Author 
Imag
ing 
Mod
ality 
Users / 
Controls (n) 
User 
age, 
mean 
(SD) 
unless 
otherwis
e stated 
Durati
on of 
use 
(y), 
mean 
(SD) 
unless 
otherwis
e stated 
User 
onset 
age 
(y), 
mean 
(SD) 
unless 
otherwis
e stated 
Use 
frequency 
in 
joints/con
es/uses, 
mean (SD) 
unless 
otherwise 
specified 
Increase 
(volume, blood flow, 
activation, 
connectivity) 
Decrease 
(volume, blood flow, activation, connectivity) 
Chronic effects on structural connectivity 
Gruber 
& 
Yurgel
un-
DTI 10 / 10 
26.8 
(3.6) 
- 
14.1 (-
) 
39.4 /w No significant changes 
ACCEPTED MANUSCRIPT
AC
CE
PT
ED
 M
AN
US
CR
IPT
 
Todd 
(2005) 
Delisi 
et al. 
(2006) 
DTI 10 / 10 
23.0 
(4.4) 
>1y <18 
r:1 /d to 3 
/w 
No significant changes 
Arnone 
et al. 
(2008) 
DTI 11 / 11 
25.0 
(2.9) 
9.0 
(3.5) 
15.2 
(2.8) 
44.1 (29.4) 
/w 
Corpus 
Callosum 
(Mean 
Diffusivity) 
- 
Kim et 
al. 
(2011) 
DTI 
(with 
grap
h 
theor
y) 
12 / 13 
19.3 
(0.9) 
3.3 
(2.5) 
16.0 
(2.3) 
5 (1.7) /w 
Clustering 
Coefficients 
Global network efficiency / Altered cingulate connectivity 
Zalesky 
et al. 
(2012) 
DW-
MRI 
59 / 33 
33.4 
(10.9) 
15.6 
(9.5) 
16.7 
(3.3) 
147 (142) / 
m 
- 
R fimbria of HPC (fornix), splenium of corpus callosum, 
commissural fibres [changes associated with age of onset 
use] 
Gruber 
& 
Yurgel
un-
Todd 
(2011) 
DTI 15 / 15 
25.0 
(8.7) 
10.1 
(9.7) 
14.9 
(2.5) 
25.5(27.8) 
/w 
R Genu 
(Higher trace) 
L Frontal (FA) 
Filbey 
& 
Dunlop 
(2014) 
DTI 31 D / 24 ND 
24.4 
(6.9) 
[D] / 
24.4 
(8.0) 
[ND] 
5.8 
(5.8) 
[D] / 
7.6 
(7.8) 
[ND] 
18.1 
(3.6) 
[D] / 
17.0 
(2.6) 
[ND] 
80.8 (14.3) 
[D] / 82.5 
(14.8) [ND] 
/last 90d 
Amygdala-ACG 
[D] 
connectivity, 
NAc-OFC-HPC 
[ND] 
connectivity 
- 
Becker 
et al. 
(2015) 
DTI 
23 / 0 
baseline, 2y 
19.5 
(0.7) 
>1y 
15.4 
(1.2) 
3032.6 
(2395.3) / 
last y 
[baseline] 
- 
Growth of superior longitudinal fasciculus, L superior 
frontal WM, L corticospinal tract, R anterior thalamic 
radiation (FA) 
R central/posterior superior longitudinal fasciculus, 
corticospinal tract, posterior cingulum (diffusion) 
Epstein 
& 
DTI 
19 [D] / 34 
EOSS 
16.6 
(1.5) 
- <17 
712 (399) 
d/lifetime 
- 
L inferior longitudinal fasciculus, L inferior-fronto-occipital 
fasciculus (FA) 
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Kumra 
(2015) 
(occasional 
cannabis 
users) / 29 
controls 
baseline, 
18m 
Orr et 
al. 
(2016) 
DTI 
& 
sMRI 
466 (Human 
Connectome 
Project) 
r22-35 - 
r <14 
to >21 
r 1-5 
/lifetime 
to >1000 
/lifetime 
- 
 
WM coherence in superior & inferior longitudinal 
fasciculus, corpus callosum (major & minor forceps, 
occipital & frontal lobe levels); changes correlate with age 
of onset of cannabis use only - no group differences in 
cannabis users vs non-users. 
ACG = anterior cingulate gyrus, d = day, D = dependent cannabis user, DTI = diffusion tensor imaging, DW-MRI = diffusion-weighted magnetic 
resonance imaging, EOSS = early-onset schizophrenia spectrum disorder, FA = fractional anisotropy, fMRI = functional magnetic resonance 
imaging, HPC = hippocampus, L = left, m = month, NAc = nucleus accumbens, ND = non-dependent cannabis user, OFC = orbitofrontal cortex, r = 
range, R = right, SD = standard deviation, sMRI = structural magnetic resonance imaging, w = week, WM = white matter, y = year. 
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Resting cerebral blood flow and metabolism 
  
A range of neuroimaging techniques have been used to measure the long-term effects of 
THC on CBF including [
133
Xe] cerebral blood flow tomography, H2[
15
O]- PET, single-photon 
emission computed tomography, fMRI and ASL. [
133
Xe] inhalation comparing CBF in long-term 
cannabis users after cessation compared to controls has found lower global (Tunving et al., 1986) 
and frontal (Lundqvist et al., 2001) CBF, although this has not been replicated in all studies 
(Mathew et al., 1986). In contrast to findings in “inexperienced users”, [133Xe] imaging found 
that there was no significant effect of acute inhaled cannabis on CBF in “experienced users” 
relative to placebo (Mathew et al., 1989). More recent studies using ASL (Jacobus et al., 2012) 
have found that cannabis users have reduced CBF in the left superior and middle temporal gyri, 
left insula, medial frontal gyri and left supramarginal gyrus alongside increased CBF in the right 
precuneus. Studies using H2 [
15
O]-PET have found reductions of 18% in regional CBF in ventral 
PFC and bilateral posterior cerebellar hemisphere in “frequent” cannabis users, compared to 
controls after 26 hours of abstinence (Block et al., 2000b).  Paradoxically, in one study (Wilson 
et al., 2000) earlier age of first cannabis use was associated with relatively higher global CBF 
compared to those who started later. More novel MRI methods including dynamic susceptibility 
contrast MRI and phase contrast MRI have yielded conflicting results including increased blood 
volume in the right frontal and temporal cortices and cerebellum (Sneider et al., 2008) in users, 
which were not present upon four weeks cessation, and increased striatal CBF (Filbey et al., 
2018). 
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A limited number of studies have investigated brain metabolism in cannabis users with 
[
18
F]FDG PET. Wiers et al. (2016) found that people with cannabis use disorder had frontal 
hypometabolism, including in the anterior cingulate, which was associated with negative 
emotionality. Upon methylphenidate challenge cannabis users had an attenuated whole-brain 
glucose metabolic response with the most pronounced effects in the striatum.  Within cannabis 
users methylphenidate-induced metabolic increases in the putamen were inversely related with 
addiction severity. Of note, there were significant sex effects, such that both the group 
differences at baseline in frontal metabolism and the attenuated regional brain metabolic 
responses to methylphenidate were observed in female but not male users.  The hypofrontality 
findings above are in line with those of one previous study which found that cannabis users had 
hypometabolism in the OFC, precuneus and putamen (Sevy et al., 2008).  Importantly, there was 
no relationship between dopamine receptor availability and glucose metabolism (Sevy et al., 
2008). 
  
Functional connectivity 
  
Long-term cannabis use is associated with a range of functional connectivity alterations. 
Cannabis abuse and dependence have also been associated with increased local functional 
connectivity in the ventral striatum and midbrain (Manza et al., 2018) alongside striatofrontal 
hypoconnectivity (Filbey & Dunlop, 2014; Lichenstein et al., 2017). This is associated with 
escalating patterns of use, anhedonia and lower educational achievement at age 22 years 
(Lichenstein et al., 2017). In addition, cannabis users showed increased functional connectivity 
in the ventral part of the posterior cingulate cortex (PCC) and decreased functional connectivity 
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in the dorsal PCC-precuneus junction alongside hippocampal hypoconnectivity such that 
aberrant default mode and hippocampal connectivity were related to memory impairments (Pujol 
et al., 2014).  Compared to controls, male cannabis users had increased resting state activity in 
diffuse regions corresponding to those with high CB1R expression (Cheng et al., 2014). 
Increased functional connectivity observed between these regions and increased resting state 
activity was related to impulsivity. In line with structural hyperconnectivity of the OFC seen in 
young cannabis users described above there is evidence that users have increased functional 
connectivity in the OFC and the minor forceps which was associated with age of onset of drug 
use (Filbey & Dunlop, 2014).  This finding was replicated in a separate study using seeds in the 
OFC (Lopez-Larson et al., 2015) whereby increased orbitofrontal connectivity with the PFC and 
ACC was observed in adolescent heavy cannabis users (Lopez-Larson et al., 2015). Importantly, 
this was related to both cannabis use and impulsivity. 
  
Executive function 
  
Cannabis use is associated with executive dysfunction.  Using the Iowa Gambling Task 
(Bechara et al., 1994) and H2[
15
O]- PET (Bolla et al., 2005; Vaidya et al., 2012) there is 
evidence, including dose-effects, that chronic cannabis users have prefrontal dysfunction. These 
findings were extended using fMRI whereby heavy cannabis users had hyperactivation to win 
versus loss evaluation in the right OFC, right insula, and left superior temporal gyrus compared 
to non-users (Cousijn et al., 2013). One study (Gruber et al., 2017) examined the effects of three 
months exposure to “medical” cannabis. While that study reported improved task performance 
and purported normalisation of aberrant BOLD response, the clinical groups were 
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heterogeneous, there was no placebo group, and the doses of phytocannabinoids were not 
reported, which limits the inferences that can be made.  
  
  
Cannabis users exhibit deficits in attention, however there are conflicting findings in the 
neuroimaging literature regarding underlying mechanisms. For example, both increases and 
decreases in right PFC function have been reported (Abdullaev et al., 2010; Chang et al., 2006b) 
as well as no significant effects (Jager et al., 2006). In a study of the interactions between 
attention-deficit hyperactivity disorder and cannabis use with a prospective cohort (Kelly et al., 
2017) there were distinct effects of diagnosis and cannabis use on network connectivity.  
Importantly, that study did not report cannabis-associated exacerbations of impaired network 
connectivity, which were found in patients with attention-deficit hyperactivity disorder.  
However, this may be due to cannabis users who were regular but not daily users.  Taken 
together there is evidence that disrupted executive network function may underlie the 
behavioural attentional deficits seen in cannabis use. 
  
In terms of response inhibition, there is electrophysiological evidence from a drug Stroop 
task that cannabis users have an enhanced early attentional bias to drug-related cues (Asmaro et 
al., 2014). Using the Stroop and Go/No-go tasks, cannabis users have impaired response 
inhibition compared to non-users (Gruber & Yurgelun-Todd, 2005; Hester et al., 2009) 
associated with anterior cingulate hypoactivation, which has also been reported in the absence of 
behavioural differences in performance (Eldreth et al., 2004). In terms of connectivity, Go/No-go 
and stop-signal experiments (Behan et al., 2014; Filbey & Yezhuvath, 2013) found that poor 
ACCEPTED MANUSCRIPT
AC
CE
PT
ED
 M
AN
US
CR
IPT
 
inhibitory control in cannabis users was related to parieto-cerebellar hyperconnectivity and 
cannabis dependence was associated with fronto-nigro-subthalamic hyperconnectivity during 
successful response inhibition.   
  
There is converging evidence that cannabis use is associated with working memory 
impairments associated with hyperactivation and hyperconnectivity of working memory circuits 
particularly in the PFC (Becker et al., 2010a; Colizzi et al., 2015; Jager et al., 2010; Kanayama 
et al., 2004; Tervo-Clemmens et al., 2018). These effects have been associated with total 
cannabis exposure (Tervo-Clemmens et al., 2018) which may be mediated by CB1R genotype 
(Colizzi et al., 2015).  Whilst a study in chronic heavy users did not find a significant difference 
between cannabis users and controls, there was a disturbance of the normal relationship between 
performance improvement and concomitant changes in network function (Cousijn et al., 2013). 
Working memory effects may predict severity of subsequent drug use (Cousijn et al., 2014). 
However, these effects do not appear to persist into abstinence (Jager et al., 2006). 
  
 
Motor performance 
  
Studies have used finger-sequencing and finger-tapping to measure fine motor function.  
Cannabis use was associated with impaired psychomotor performance and increased 
supplementary motor cortex activation in one study (King et al., 2011). However, when studying 
withdrawal from cannabis there is evidence (Pillay et al., 2004) of decreased task-induced 
activation in supplementary motor area which persists to 28 days of cessation (Pillay et al., 
2008). However, these findings were not replicated in a separate study (Murphy et al., 2006).  
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Reward processing 
  
Cross-sectional studies using the MID task have provided mixed results. There is 
evidence of ventral striatal hyperactivity during reward anticipation (Nestor et al., 2010) and 
putamen and caudate hyperactivity during anticipation of neutral trials (Jager et al., 2013). 
However, other studies have not found differences between cannabis users and controls on 
striatal response to reward anticipation (Enzi et al., 2015; Karoly et al., 2015) or report a blunted 
caudate response to reward anticipation in chronic cannabis users compared to non-smoking and 
smoking control groups (van Hell et al., 2010). Importantly, a longitudinal study following 108 
volunteers at age 20, 22 and 24 years found that cannabis use was associated with blunted NAc 
response to reward anticipation at subsequent time points; there was no evidence for associations 
in the reverse direction (Martz et al., 2016).  
 
In terms of feedback trials on the MID task, cross-sectional findings have also been 
mixed. Cannabis users have shown a blunted response to reward feedback in the left caudate and 
inferior frontal gyrus (Enzi et al., 2015) and increased right putamen response to reward 
feedback relative to smokers and non-using controls (van Hell et al., 2010).  However, other 
studies have not found differences between cannabis users and controls in reward feedback, but 
instead have found striatal hyperactivation during reward anticipation (Jager et al., 2013). There 
is also evidence for blunted response to reward loss and loss avoidance in the left insula (Nestor 
et al., 2010). Blunted responses to reward loss may be clinically relevant, as ventral striatal 
hyperactivation during loss feedback predicted abstinence at 21 days in a group of dependent 
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users following behavioural treatment for cannabis cessation (Yip et al., 2014). In an fMRI task 
of passive listening to preferred and neutral instrumental music (Ford et al., 2014) cannabis users 
did not show significant differences in activation compared to non-users and people experiencing 
depression.  However, depressed cannabis users exhibited increased activation to preferred music 
in the putamen, anterior cingulate and right frontal regions compared to non-users and non-
depressed users. This suggests that depression associated with cannabis use may be associated 
with disrupted reward processing. 
  
Learning and memory 
  
Chronic cannabis use has been associated with negative effects across learning and 
memory including impaired recall (reviewed by Bossong et al., (2014) and Broyd et al., (2016)). 
Several mechanisms may be underlying this in addition to working memory dysfunction 
described earlier.  For example, impaired error-related learning is associated with hypoactivity of 
the anterior cingulate and left hippocampus in cannabis users (Carey et al., 2015). A study using 
H2[
15
O]-PET found that chronic cannabis users have lower prefrontal blood flow and altered 
hippocampal lateralization during memory processing (Block et al., 2002). There is evidence that 
cannabis users and recently abstinent users exhibit parahippocampal dysfunction during 
encoding and retrieval (Becker et al., 2010b; Jager et al., 2007; Nestor et al., 2008). Episodic 
memory dysfunction in cannabis use, including increased risk of false memories, has been 
related to altered medial temporal lobe morphology (Smith et al., 2015b) and function (Riba et 
al., 2015). In terms of spatial memory, compared to controls, cannabis users had right 
parahippocampal hypoactivation during a virtual water maze (Sneider et al., 2013).  
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 Emotional Processing 
  
Cannabis users show behavioural impairments in the recognition of facial affect (Platt et 
al., 2010) and these were found to be robust after accounting for sex differences and schizotypal 
personality traits (Hindocha et al., 2014). Studies in adult heavy and regular cannabis users have 
found decreases in BOLD response within the cingulate, frontal cortex and the amygdala 
including during negative emotional stimuli presentation (Gruber et al., 2009; Zimmermann et 
al., 2017). This was alongside hypoconnectivity between the amygdala and DLPFC in active 
users and orbitofronto-striatal and amygdalar hyperconnectivity following 28 days of abstinence 
(Zimmermann et al., 2018). 
  
 CB1 receptor availability 
  
Though the regional brain pattern of reduction in CB1R availability differed between 
studies, active cannabis use is associated with reduced CB1R availability that appears to 
normalise after abstinence. The first study (Hirvonen et al., 2012) measured CB1R binding using 
the selective radioligand [
18
F]FMPEP-d2 in 30 heavy cannabis users compared to 28 controls. 
This showed a 20% reduction in binding in the neocortex and limbic cortex of cannabis users 
which normalised after 4 weeks of monitored abstinence. The former finding was supported by a 
subsequent PET study (Ceccarini et al., 2015) of 10 chronic cannabis users using the CB1R 
inverse agonist radiotracer [
18
F]MK-9470 which showed a global 11.7% decrease in availability 
compared to controls. Region-of-interest analysis showed significant reductions in CB1R 
expression in the temporal lobe, ACC, PCC and NAc. A greater reduction in a similar study 
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(D'Souza et al., 2016) using a different CB1R specific ligand ([
11
C]OMAR) demonstrated a 15% 
reduction in CB1R availability in limbic, cortical and striatal brain regions at 8-12 hours after last 
cannabis exposure. This reduction then rapidly normalised with non-significant reductions in 
CB1R availability evident after only two days abstinence.  
 
The dopaminergic system 
  
  
Several studies have imaged dopaminergic function in cannabis users.  Using PET, 
striatal dopamine synthesis capacity was reduced in cannabis users and this was driven by users 
who were dependent on the drug (Bloomfield et al., 2014a). Importantly, within users, 
motivation levels were related to striatal dopamine synthesis capacity in the associative striatum 
(Bloomfield et al, 2014b).  Two further studies using PET showed a reduction in striatal 
dopamine release in cannabis users in response to amphetamine challenge (van de Giessen et al., 
2017; Volkow et al., 2014), however, a consistent pattern was not observed in recently abstinent 
cannabis users (Urban et al., 2012) suggesting this reduction is dependent on active use. The 
reduction in dopamine release also correlated with cognitive deficits including poor working 
memory (van de Giessen et al., 2017). These findings were supported by another PET study 
showing reduced metabolic response in the striatum in cannabis users after a methylphenidate 
challenge (Wiers et al., 2016). Another study that examined the interaction between chronic 
cannabis use and stress-induced dopamine release found no significant alteration in dopamine 
release, but did find a significant positive correlation between duration of cannabis use and 
dopamine release in the limbic striatum (Mizrahi et al., 2013).  Further evidence of reduced 
dopaminergic activity in cannabis users came from PET imaging to examine dopamine 
transporter availability, showing lower dopamine transporter availability in the ventral striatum, 
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the midbrain, the middle cingulate and the thalamus (ranging from -15 to -30%; Leroy et al., 
2012). Several studies (Urban et al., 2012; van de Giessen et al., 2017; Volkow et al., 2014) have 
shown no significant striatal dopamine 2 receptor (D2R) availability differences between 
cannabis or ex-cannabis users and cannabis naïve participants. Nonetheless, one study (Albrecht 
et al., 2013) found a strong negative association between D2R availability and level of current 
cannabis use suggesting a potential dose-dependent effect. Similarly, another study (Urban et al., 
2012) found a negative relationship between D2R availability and age of first use. 
  
  
Glutamatergic and GABAergic systems 
  
Five studies have investigated in vivo differences in glutamate-related metabolites in 
cannabis users (Colizzi et al., 2016). All of these studies used 
1
H magnetic resonance 
spectroscopy (MRS) in chronic cannabis users versus controls. The first study to do this (Chang 
et al., 2006a) found a 9.5% reduction in basal ganglia glutamate metabolite levels in 24 daily 
cannabis users in comparison to 30 non-using controls. This study used the same model of 
analysis to look at frontal white matter glutamate metabolite levels in a sample including 42 
people who were human immunodeficiency virus positive, half of whom were cannabis users, 
compared to 24 healthy cannabis users and 30 that were cannabis naïve (total n = 96). This 
further analysis showed even greater reductions (12-13%) in glutamate metabolite levels in 
chronic cannabis users, with healthy cannabis users having lower levels. The reduction in 
glutamate metabolite levels found in the basal ganglia and frontal white matter was also shown 
by two different studies (Prescot et al., 2011; Prescot et al., 2013) from the same research team 
(2011, n=34; 2013, n = 29) that found a similar 15% reduction in glutamate signal in the ACC 
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and a concomitant reduction in GABA signal. However, these reductions in the same brain 
region were not found in another study (Sung et al., 2013), though this had a smaller sample size 
(n=8) and subjects were concurrently using methamphetamine.  Only one imaging study to date 
(Muetzel et al., 2013) has looked at glutamate profiles of heavy cannabis users (n=27) versus 
healthy controls (n=26) in the striatum. This found no significant reduction in glutamate levels in 
the dorsal striatum but did find lower levels of glutamate and glutamine in female cannabis users 
but not males, compared to controls, suggesting a possible sex related difference.  
  
These samples differed with respect to period of abstinence from cannabis prior to 
imaging.  The first study (Chang et al., 2006a) had no specific criteria regarding abstinence from 
cannabis use prior to scanning while another sample (Muetzel et al., 2013) only included those 
who were abstinent for over 12 hours. The two studies (Prescot et al., 2011; Prescot et al., 2013) 
showing significant reductions in glutamate metabolite levels in the ACC reported 54% of 
cannabis using participants had used cannabis in the preceding 24 hours. This could lead to 
significant variation in THC levels in the brain and animal studies have shown paradoxical 
outcomes on glutamate levels dependent on acute or chronic exposure to THC (Castaldo et al., 
2010). Participants also differed significantly with regard to existing psychopathology. Three 
studies (Muetzel et al., 2013; Prescot et al., 2011; Prescot et al., 2013) included participants who 
had existing mental health problems, the first two of which included participants receiving 
antidepressant treatment for depression, which could impact glutamatergic systems (Duman, 
2014; Sanacora et al., 2012).  Outcome metabolite measures with MRS imaging also differed 
significantly. Two studies (Muetzel et al., 2013; Sung et al., 2013) measured both glutamate and 
glutamine metabolites, while all others only accounted for glutamate. Measurements also varied 
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with regard to correction comparison of metabolite levels differing between correcting against 
water (Prescot et al., 2011; Prescot et al., 2013), cerebrospinal fluid (Chang et al., 2006a), total 
creatinine (Muetzel et al., 2013) or phosphocreatinine and creatinine (Sung et al., 2013). 
  
Other systems 
  
Using [
18
F]2-F-A-85830 PET, Brody et al. (2016) found that tobacco smokers with 
concurrent heavy cannabis use (defined as over 22 days per months) had higher α4β2 nicotinic 
acetylcholine receptor availability than smokers without drug use. Interestingly, findings in 
cannabis using smokers were similar to those seen in heavy caffeine users. Given the very 
different pharmacology of cannabis and caffeine, this suggests that the increased nicotinic 
acetylcholine receptor availability in tobacco users may not be specifically mediated by heavy 
cannabis use. 
 
Given the putative neurotoxic effects of cannabis (Pope et al., 2010), there is interest in 
the impact of heavy cannabis use on regional levels of N-acetylaspartate (NAA), a proxy marker 
of neuronal integrity (Moffett et al., 2007). The first MRS study on this subject found that the 
NAA to total creatine ratio was decreased in the DLPFC of heavy cannabis users versus controls 
(Hermann et al., 2007). A decrease in NAA to total creatine ratio was since replicated in the 
neighbouring inferior frontal gyrus of polydrug users, which was negatively correlated with 
degree of cannabis use only (Cowan et al., 2009), and the mid-frontal anterior cingulate area of 
methamphetamine and cannabis users versus methamphetamine users alone (Sung et al., 2013). 
These results suggest that heavy cannabis use may cause disruption of neuronal architecture in 
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frontal structures. This corroborates findings of decreased orbitofrontal gyrus (Filbey et al., 
2014)  and ACC (Hill et al., 2016) volumes, decreased resting state CBF to the ACC (Wiers et 
al., 2016) and orbitofrontal gyrus (Sevy et al., 2008), and alterations in ACC (Carey et al., 2015; 
Ford et al., 2014), inferior frontal gyrus (Enzi et al., 2015) and DLPFC (Jager et al., 2007) 
activity during emotional processing, reward and learning in chronic cannabis users. Decreases 
in NAA were also reported in the hippocampus of cannabis users relative to controls, alongside a 
reduction in hippocampal volume (Yücel et al., 2016). However these findings were not present 
in those with evidence of CBD exposure, or in abstinent users. These findings are consistent with 
a protective role of CBD on hippocampal dependent memory (Englund et al., 2013; Morgan et 
al., 2010) and for recovery of impaired performance following abstinence (Schreiner & Dunn, 
2012; Scott et al., 2018). 
Table 2.3: Neuroimaging studies of the chronic effects of cannabis on cerebral blood flow and metabolism, and functional 
connectivity.  
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into stable-
high use [A], 
escalating 
use [B], 
stable-low 
use [C]) 
- 
R
e
s
t
i
n
g 
20.0 
(0.0) 
- 
15.7 
(2.0) 
9.5 (12.2) /m NAc-MPFC [A / C] NAc-MPFC [B] - 
Ma
nza 
et 
al. 
(20
18) 
fMRI 
30 / 30  
[Human 
Connectome 
Project] 
- 
R
e
s
t
i
n
g 
29.2 
(3.1) 
- - - 
Ventral striatum, 
Midbrain, Brainstem, 
Lateral thalamus 
- - 
A = stable-high use, ACC = anterior cingulate cortex, ACG = anterior cingulate gyrus, ASL = arterial spin labelling, B = escalating use, C = stable-
low use, CB1R = endocannabinoid 1 receptor, CBF = cerebral blood flow, CMRO2 = Cerebral Metabolic Rate of Oxygen, d = day, D = dependent 
users, DTI = diffusion tensor imaging, F = female, fMRI = functional magnetic resonance imaging, FDG = fludeoxyglucose, h = hour, HPC = 
hippocampus, L = left, m = month, M =male, MPFC = medial prefrontal cortex, NAc = nucleus accumbens, ND = non-dependent users, OEF = 
Oxygen Extraction Fraction, OFC = orbitofrontal cortex, PCC = posterior cingulate cortex, PC-MRI = phase contrast magnetic resonance imaging, 
PET = positron emission tomography, PFC = prefrontal cortex, r = range, R = right, SPECT = single photon emission computed tomography, SD = 
standard deviation, THC = Δ9-tetrahydrocannabinol, TOFA = time of flight angiogram, TRUST-MRI = T2 relaxation under spin tagging magnetic 
resonance imaging, VPFC = ventral prefrontal cortex, w = week, y = year. 
 
Table 2.4: Neuroimaging studies of the chronic effects of cannabis on executive function and motor performance.  
 
Auth
or 
Im
agi
Users / 
Controls 
Pre-
trial 
Activity 
Mean 
User 
Duration of 
use, mean 
Use 
onset 
Use 
frequen
Increase 
(volume, blood flow, 
Decrease 
(volume, blood flow, 
Ta
sk 
ACCEPTED MANUSCRIPT
AC
CE
PT
ED
 M
AN
US
CR
IPT
 
ng 
M
od
ali
ty 
(n) unless 
otherwise 
stated 
abstin
ence, 
mean 
days 
(SD) 
unless 
otherwis
e stated 
Age 
(SD) 
years (SD) age (SD) cy in 
joints/c
ones/us
es, 
mean 
(SD) 
unless 
otherwise 
stated 
activation, connectivity) activation, 
connectivity) 
Pe
rfo
rm
an
ce 
(ca
nn
abi
s 
us
er 
vs 
co
m
pa
ris
on 
gr
ou
p) 
Chronic effects on executive function 
Eldre
th et 
al. 
(200
4) 
H2
1
50 
PE
T 
11 / 11 1 (-) 
Stroop 
Task 
25 (-) 7.5 (-) 15.7 (-) 34.7 /w HPC L ACC, L lateral PFC 
N
o 
sig
nif
ic
an
t 
ch
an
ge 
Kana
yama 
et al. 
(200
4) 
fM
RI 
12 / 10 
r6-
36h 
Spatial 
Workin
g 
Memor
y Task 
37.9 
(7.4) 
- - 
19,200 
(-) 
/lifetime 
PFC, ACC, basal ganglia - 
N
o 
sig
nif
ic
an
t 
ch
an
ACCEPTED MANUSCRIPT
AC
CE
PT
ED
 M
AN
US
CR
IPT
 
ge 
Bolla 
et al. 
(200
5) 
H2
1
5
0 
PE
T 
11 / 11 28 (-) 
Iowa 
Gambli
ng Task 
26 (-) 7.9 (-) - 41 (-) /w 
L cerebellum (Moderate 
Users>Heavy Users) 
R OFC, R DLPFC 
(Moderate 
Users>Heavy Users) 
↓
Pe
rf
or
m
an
ce 
sc
or
e 
Grub
er & 
Yurg
elun-
Todd 
(200
5) 
fM
RI 
& 
DT
I 
9 / 9 - 
Stroop 
Task 
26.8 
(3.6) 
- 14.1 (-) 
39.4 (-) 
/w 
Midcingulate cortex ACC 
↑
Co
m
mi
ssi
on 
er
ro
rs 
Chan
g et 
al. 
(200
6b) 
fM
RI 
24 [12 
abstinent, 
12 active] 
/ 19 
r4-
24h 
Visual 
Attenti
on Task 
27.9 
(10.8) 
[active], 
29.6 
(8.7) 
[abstin
ent] 
- 
15.5 
(0.9) 
[active], 
14.7 
(0.4) 
[abstine
nt] 
27.9 
(1.1) 
[active], 
26.7 
(1.4) 
[abstine
nt] /m 
Various frontal, parietal, 
occipital regions 
R PFC, medial and 
dorsal parietal 
cortex, medial 
cerebellar regions 
(cerebellar changes 
normalised with 
abstinence) 
N
o 
sig
nif
ic
an
t 
ch
an
ge 
Jager 
et al. 
(200
6) 
fM
RI 
10 / 10 >7 
Selectiv
e 
Attenti
on Task 
22.7 
(4.2) 
7.1 (3.9) - 
350 (-) 
/y 
[median
] 
No Significant Changes 
N
o 
sig
nif
ic
an
t 
ACCEPTED MANUSCRIPT
AC
CE
PT
ED
 M
AN
US
CR
IPT
 
ch
an
ge 
Hest
er et 
al. 
(200
9) 
fM
RI 
16 / 16 
1.60 
(2) 
Go/No-
Go Task 
24.6 
(1.5) 
8.2 (1.3) 
16.4 
(0.7) 
76.3 
(17.7) 
/m 
- ACC, R insula 
↓
Er
ro
r 
a
w
ar
en
es
s 
Abdu
llaev 
et al. 
(201
0) 
fM
RI 
14 / 14 2 (-) 
Attenti
on 
Networ
k Task, 
Use 
Genera
tion 
Task 
19.5 
(0.8) 
5.1 (-) 14.7 (-) 
132 (-) 
/y 
R PFC - 
↑
Re
ac
tio
n 
ti
m
e, 
↑ 
Er
ro
rs 
Beck
er et 
al. 
(201
0a) 
fM
RI 
26 [early-
onset 
<16y 
cannabis 
users] / 
17 [late-
onset 
>16y] 
- 
Verbal 
Workin
g 
Memor
y 
21.0 
(2.8) 
[early 
onset], 
24.5 
(3.4) 
[late 
onset] 
4.48 (3.4) 
[early onset], 
3.88 (2.6) 
[late onset] 
13.9 
(1.0) 
[early 
onset], 
17.0 
(1.5) 
[late 
onset] 
17.2 
(10.7) 
[early 
onset], 
9.8 (9.9) 
[late 
onset] 
/m 
L superior parietal lobe 
(early-onset) 
- 
↑
Re
ac
tio
n 
ti
m
e 
in 
ea
rly
-
ACCEPTED MANUSCRIPT
AC
CE
PT
ED
 M
AN
US
CR
IPT
 
on
se
t 
on 
1-
ba
ck 
ta
sk 
Jager 
et al. 
(201
0) 
fM
RI 
21 / 24 
35.7 
(29.4) 
Rule 
Based 
Learnin
g 
17.2 
(1.0) 
- 
13.2 
(2.3) 
741.0 
(772.0) 
/y 
Prefrontal regions (novel 
task vs automised task)  
N
o 
sig
nif
ic
an
t 
ch
an
ge 
Vaidy
a et 
al. 
(201
2) 
H2
1
50 
PE
T 
46 / 38 1 (-) 
Iowa 
Gambli
ng Task 
24.3 
(3.9) 
6.2 (3.2) 
16.4 
(1.9) 
24.6 
(6.2) /m 
VMPFC, cerebellum - 
N
o 
sig
nif
ic
an
t 
ch
an
ge 
on 
st
an
da
rd 
IG
T, 
↓
ACCEPTED MANUSCRIPT
AC
CE
PT
ED
 M
AN
US
CR
IPT
 
pe
rf
or
m
an
ce 
on 
va
ria
nt 
IG
T 
Cousi
jn et 
al. 
(201
3) 
fM
RI 
32 / 41 
Baseline, 
6m 
1.6 
(2.2) 
Iowa 
Gambli
ng Task 
21.9 
(2.4) 
2.9 (2.0) - 
4.9 (2.1) 
/w 
R OFC, R insula, L superior 
temporal gyrus 
- 
N
o 
sig
nif
ic
an
t 
ch
an
ge 
Filbe
y & 
Yezh
uvat
h 
(201
3) 
fM
RI 
44 [D] / 
30 [ND] 
3 (-) 
Stop 
Signal 
Task 
23.7 
(6.5) 
[D], 
24.8 
(8.2) 
[ND] 
5.5 (5.5) [D], 
7.7 (7.5) 
[ND] 
17.3 
(2.5) 
[D], 
17.4 
(2.6) 
[ND] 
3.4 (2.0) 
[D], 4 
(4.0) 
[ND] /d 
R frontal-control network, 
substantia nigra-
subthalamic nucleus 
network 
- 
N
o 
sig
nif
ic
an
t 
ch
an
ge 
Asma
ro et 
al. 
(201
4) 
EE
G 
& 
fM
RI 
13 / 15 1 (-) 
Stroop 
Task 
22.3 
(3.0) 
- - 
5.8 (1.6) 
/w 
EEG: Early positive 
enhancement L frontal 
scalp, posterior / fMRI: L 
VMPFC, MOFC. 
- 
↓
Ac
cu
ra
cy 
ACCEPTED MANUSCRIPT
AC
CE
PT
ED
 M
AN
US
CR
IPT
 
(d
ru
g-
co
nt
ai
ni
ng 
bl
oc
ks
) 
Beha
n et 
al. 
(201
4) 
fM
RI 
17 / 18 - 
Go/No-
Go Task 
16.5 
(0.2) 
- 
13.0 
(0.2) 
178.4 
(38) /m 
Parietal-Cerebellar 
Network 
- 
↓
Ac
cu
ra
cy 
Cousi
jn et 
al. 
(201
4) 
fM
RI 
32 / 41 
Baseline, 
6m 
1.8 
(2.3) 
N-back 
Workin
g 
Memor
y Task 
21.9 
(2.4) 
3.0 (1.9) 
18.9 
(2.4) 
4.9 (2.1) 
/w 
Working-Memory 
Network (VLPFC, DLPFC, 
premotor cortex, 
paracingulate cortex, 
inferior parietal cortex) - 
predicted weekly cannabis 
use at 6 months 
- 
N
o 
sig
nif
ic
an
t 
ch
an
ge 
Coliz
zi et 
al. 
(201
5) 
fM
RI 
91 / 117 
[CNR1 
rs140697
7 AA 
subjects / 
G carriers] 
- 
2-Back 
Workin
g 
Memor
y Task 
26.7 
(6.3) 
93.2% used 
for >5 years 
[AA 
subjects], 
93.75% used 
for >5years 
[G carriers] 
25.0 
(42.4) 
[AA 
subjects
], 10 
(31.25) 
[G 
carriers] 
- L VLPFC (G allele carriers) - 
↓
Ac
cu
ra
cy 
(G 
ca
rri
er
s) 
ACCEPTED MANUSCRIPT
AC
CE
PT
ED
 M
AN
US
CR
IPT
 
Grub
er et 
al. 
(201
7) 
fM
RI  
45 
[medical 
cannabis 
users] / 0 
Baseline, 
3m 
No 
abstin
ence 
Multi-
Source 
Inferen
ce Test 
(MSIT) 
50.6 
(13.2) 
- - 
5.3 (2.0) 
/w 
ACC 
Normalisation of 
aberrant BOLD 
signal at 3 months 
vs baseline 
↑
Pe
rf
or
m
an
ce 
at 
3
m 
Terv
o-
Clem
mens 
et al. 
(201
8) 
fM
RI 
14 
[occasion
al users] / 
46 
[chronic 
users] / 
15 [non-
users] 
- 
Workin
g 
Memor
y Task 
28.2 
(0.7) 
- 
15.1 
(2.3) 
1.4 (2.7) 
/d 
DLPFC 
PCC (correlates with 
age of onset of 
cannabis use) 
Ov
er
all 
↑ 
pe
rf
or
m
an
ce 
in 
ca
nn
ab
is 
us
er
s, 
↑
Re
ac
tio
n 
ti
m
es 
(e
ACCEPTED MANUSCRIPT
AC
CE
PT
ED
 M
AN
US
CR
IPT
 
arl
ier 
ag
e 
of 
on
se
t 
vs 
lat
er 
ag
e 
of 
on
se
t) 
Chronic effects on motor performance 
Pillay 
et al. 
(200
4) 
fM
RI 
9 / 16 
r0.3-
1.5 
Finger 
Sequen
cing 
37.3 
(6.7) 
21.0 (4.9) 
18.4 
(5.9) 
- - SMA - 
Murp
hy et 
al. 
(200
6) 
fM
RI 
20 / 25 - 
Finger 
Tapping 
Task 
23.0 (-) 6.5 (-) - 6 (-) /w No Significant Changes - 
Pillay 
et al. 
(200
8) 
fM
RI 
11 / 16 28 (-) 
Finger 
Tapping 
Task 
37.7 
(6.2) 
- - - - SMA - 
King 
et al. 
(201
1) 
fM
RI 
30 / 30 0.5 (-) 
Multipl
e 
Psycho
motor / 
Motor 
Tasks 
21 (-) 
[M), 
22.5 (-) 
[F] 
6.5 (-) [M), 
5.3 (-) [F] 
14.5 
[M], 
16.0 [F] 
6.5 (-) 
/w 
SMA - 
↓
Ps
yc
ho
m
ot
ACCEPTED MANUSCRIPT
AC
CE
PT
ED
 M
AN
US
CR
IPT
 
or 
sp
ee
d 
(
M 
on
ly) 
ACC = anterior cingulate cortex, BOLD = blood oxygen level dependent, CNR1 = cannabinoid receptor 1 gene, d = day, D = dependent users, 
DLPFC = dorsolateral PFC, DTI = diffusion tensor imaging, EEG = electroencephalography, F = female, fMRI = functional magnetic resonance 
imaging, h = hour, HPC = hippocampus, IGT = Iowa Gambling Task, L = left, m = month, M =male, MOFC = medial orbitofrontal cortex, ND = non-
dependent users, OFC = orbitofrontal cortex, PCC = posterior cingulate cortex, PET = positron emission tomography, PFC = prefrontal cortex, r = 
range, R = right, SMA = supplementary motor area, SD = standard deviation, VLPFC = ventrolateral prefrontal cortex, VMPFC = ventromedial 
prefrontal cortex, w = week, y = year. 
 
Table 2.5: Neuroimaging studies of the chronic effects of cannabis on reward processing, learning and memory, and 
emotional processing.  
 
Au
tho
r 
I
m
ag
in
g 
M
o
d
ali
ty 
Users / Controls 
(n) unless otherwise 
stated 
Pre-
trial 
absti
nenc
e, 
mea
n 
days 
(SD) 
unless 
other
wise 
stated 
Activit
y 
Mean User 
Age (SD) 
Duratio
n of 
use, 
mean 
years 
(SD) 
Use onset 
age (SD) 
Use frequency 
in 
joints/cones/
uses, mean 
(SD) 
unless otherwise 
stated 
Increase 
(volume, blood 
flow, activation, 
connectivity) 
Decrease 
(volume, blood 
flow, activation, 
connectivity) 
Ta
sk 
P
er
fo
r
m
a
nc
e 
(c
a
n
n
a
bi
s 
us
er 
vs 
co
m
ACCEPTED MANUSCRIPT
AC
CE
PT
ED
 M
AN
US
CR
IPT
 
p
ar
is
o
n 
gr
o
u
p) 
Chronic effects on reward processing 
Ne
sto
r et 
al. 
(20
10) 
f
M
RI 
14 / 14 9 (-) 
Monet
ary 
Incenti
ve 
Delay 
Task 
23.1 (1.2) 6.1 (-) 16.1 (0.4) 
7,258 (-) 
/lifetime 
Ventral 
striatum 
- 
N
o 
si
g
ni
fi
c
a
n
t 
c
h
a
n
g
e 
Va
n 
Hel
l et 
al. 
(20
10) 
f
M
RI 
14 [cannabis 
smokers] / 14 
[tobacco smokers] 
/  13 [non-smoking 
controls] 
>7 
Monet
ary 
Incenti
ve 
Delay 
Task 
24.0 (4..4)  - - 
3841 (2645.3) 
/lifetime 
R putamen 
(during reward 
feedback) 
(cannabis 
smokers vs 
tobacco 
smokers and 
non-smokers) 
NAc (cannabis 
and tobacco 
smokers vs non-
smokers), 
caudate 
(cannabis 
smokers vs 
tobacco 
smokers and 
non-smokers)  
(during reward 
anticipation) 
N
o 
si
g
ni
fi
c
a
n
t 
c
h
a
ACCEPTED MANUSCRIPT
AC
CE
PT
ED
 M
AN
US
CR
IPT
 
n
g
e 
Jag
er 
et 
al. 
(20
13) 
f
M
RI 
21 / 24 
35.7 
(29.
4) 
Monet
ary 
Incenti
ve 
Delay 
Task 
17.2 (1.0) - 13.2 (2.3) 
4,006 (7,555) 
/lifetime 
Striatum 
(anticipation of 
neutral trials) 
- 
N
o 
si
g
ni
fi
c
a
n
t 
c
h
a
n
g
e 
For
d 
et 
al. 
(20
14) 
f
M
RI 
15 [cannabis users] 
/ 15 [MDD] / 14 
[cannabis users 
with MDD] / 17 
[healthy controls] 
- 
Music 
Listeni
ng 
Paradig
m 
(Neutr
al and 
Preferr
ed 
Music) 
20.2 (1.3) 
[cannabis 
users], 19.9 
(1.7) [MDD + 
cannabis 
users] 
6.8 
(0.4) 
[canna
bis 
users] 
6.9 
(0.4) 
[canna
bis 
users + 
MDD] 
- 
22.0 (6.2) 
[cannabis 
users], 20.5 
(9.2) [cannabis 
users + MDD] 
/m 
Putamen, ACC, 
R frontal 
regions 
(preferred 
music, 
depressed 
cannabis users) 
- 
N
o 
si
g
ni
fi
c
a
n
t 
c
h
a
n
g
e 
Yip 
et 
f
M
20 / 20 [measured 
at 21 days of 
20 (-
) 
Monet
ary 
26.7 (2.2) 
14.4 
(3.3) 
13.4 (0.5) 
[abstinent], 
- 
Ventral 
striatum 
- 
N
o 
ACCEPTED MANUSCRIPT
AC
CE
PT
ED
 M
AN
US
CR
IPT
 
al. 
(20
14) 
RI abstinence] Incenti
ve 
Delay 
Task 
[abstin
ent], 
8.7 
(1.9) 
[non-
abstine
nt] 
14.1 (0.6) 
[non-
abstinent] 
(response to 
loss of reward, 
predicted 
abstinence at 
21 days) 
si
g
ni
fi
c
a
n
t 
c
h
a
n
g
e 
Enz
i et 
al. 
(20
15) 
f
M
RI 
15 / 15 
1.1 
(1.1) 
Monet
ary 
Incenti
ve 
Delay 
Task 
26.3 (2.9) 
8.5 
(3.0) 
15.8 (2.7) 13.3 (7.3) /w 
L caudate, 
inferior frontal 
gyrus 
- 
N
o 
si
g
ni
fi
c
a
n
t 
c
h
a
n
g
e 
Kar
oly 
et 
al. 
(20
15) 
f
M
RI 
14 [cannabis users] 
/ 34 [tobacco only] 
/ 12 [alcohol only] 
/ 17 [cannabis + 
tobacco] / 17 
[cannabis + 
tobacco + alcohol] 
>0.1 
Monet
ary 
Incenti
ve 
Delay 
Task 
15.8 (1.4) 
[cannabis 
users], 15.8 
(1.2) 
[cannabis + 
tobacco], 
15.9 (1.0) 
- 
12.9 (1.9) 
[cannabis 
only], 11.4 
(2.1) 
[cannabis + 
tobacco], 
10.5 (2.6) 
20.4 (8.9) /m 
[cannabis 
only], 24.4 
(6.5) /m 
[cannabis + 
tobacco], 24.8 
(6.9) /m 
No Significant Changes (cannabis 
users vs other groups) 
N
o 
si
g
ni
fi
c
ACCEPTED MANUSCRIPT
AC
CE
PT
ED
 M
AN
US
CR
IPT
 
/ 38 [non-using 
controls] 
[cannabis + 
tobacco + 
alcohol] 
[cannabis + 
tobacco + 
alcohol] 
[cannabis + 
tobacco +  
alcohol] 
a
n
t 
c
h
a
n
g
e 
Ma
rtz 
et 
al. 
(20
16) 
f
M
RI 
108  / 0 
(longitudinal 
cohort at age 20, 
22, 24, cross-
lagged model) 
>2 
Monet
ary 
Incenti
ve 
Delay 
Task 
20.1 (1.4), 
22.1 (1.5), 
23.8 (1.7) 
- 
15.4 (53.9) 
used 
cannabis by 
age 16 
17.5 (58.1) /y 
[age 20], 30.4 
(87.6) /y [age 
22], 31.8 
(89.9) [age 24] 
- 
NAc (reward 
anticipation) 
N
o 
si
g
ni
fi
c
a
n
t 
c
h
a
n
g
e 
Chronic effects on learning and memory 
Blo
ck 
et 
al. 
(20
02) 
H2
15
0 
P
ET 
18 / 13 
1.2 
(0.0) 
Word 
List 
Learnin
g 
- - - 18 (2) /w 
Cerebellum / 
Altered 
lateralisation in 
HPC 
PFC 
↓
P
er
fo
r
m
a
n
c
e 
Jag f 20 / 20 - Pictoria 24.5 (5.2) - - 1,900 (-) - Parahippocamp N
ACCEPTED MANUSCRIPT
AC
CE
PT
ED
 M
AN
US
CR
IPT
 
er 
et 
al. 
(20
07) 
M
RI 
l 
Memor
y Task 
/lifetime al regions, R 
DLPFC 
o 
si
g
ni
fi
c
a
n
t 
c
h
a
n
g
e 
Ne
sto
r et 
al. 
(20
08) 
f
M
RI 
14 / 14 
3.4 
(2.0) 
Face-
Name 
Pairs 
Task 
24.4 (1.4) 
7.2 
(1.1) 
17.0 (0.9) 19.1 (2.7) /m 
Parahippocamp
al gyrus 
R superior 
temporal gyrus, 
R superior 
frontal gyrus, R 
middle frontal 
gyrus, L 
superior frontal 
gyrus 
N
o 
si
g
ni
fi
c
a
n
t 
c
h
a
n
g
e 
in 
f
M
RI 
e
x
ACCEPTED MANUSCRIPT
AC
CE
PT
ED
 M
AN
US
CR
IPT
 
p
er
i
m
e
n
t 
(n
=
1
4)
, 
b
u
t 
↓
p
er
fo
r
m
a
n
c
e 
in 
c
h
r
o
ni
c 
u
s
er
s 
(n
ACCEPTED MANUSCRIPT
AC
CE
PT
ED
 M
AN
US
CR
IPT
 
=
3
5) 
in 
p
re
li
m
in
ar
y 
e
x
p
er
i
m
e
n
t 
Be
cke
r et 
al. 
(20
10
b) 
f
M
RI 
42 [21 high 
frequency users, 
21 low frequency 
users] / 0 
86.5 
(235
.7) 
Face 
Encodi
ng & 
Retriev
al Task 
22.5 (3.5) - 15.1 (2.0) 14.2 (11.0) /m 
L 
parahippocamp
al gyrus 
(encoding, high 
frequency>low 
frequency) 
- 
N
o 
si
g
ni
fi
c
a
n
t 
c
h
a
n
g
e 
Sn f 10 / 18 0.5 Morris 20.3 (3.6) 4.0 15.6 (1.2) 10.7 (5.5) /w - R ↓
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Chronic effects on emotional processing 
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15 / 15 >0.5 
Viewin
g 
Happy 
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0 
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ACC = anterior cingulate cortex, d = day, DLPFC = dorsolateral PFC, fMRI = functional magnetic resonance imaging, h = hour, HPC = 
hippocampus, L = left, m = month, MDD = major depressive disorder, MOFC = medial orbitofrontal cortex, NAc = nucleus accumbens, PET = 
positron emission tomography, PFC = prefrontal cortex, r = range, R = right, SMA = supplementary motor area, SD = standard deviation, w = 
week, y = year. 
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5. Developmental effects of cannabis 
  
Key periods for brain development occur in utero and during adolescence.  Importantly, 
prenatal exposure to cannabis may produce persistent effects on working memory and executive 
function in adulthood (Smith et al., 2006; Smith et al., 2016). Given the potential of multiple 
confounds associated with investigating the effects of in utero drug exposure and effects which 
are very distal to the exposure, further larger prospective studies are needed to corroborate these 
findings given the potential public health impact of consuming cannabis during pregnancy and 
breast-feeding.  
 
Heavy cannabis use during adolescence likely represents a critical period of vulnerability 
to cannabis-induced changes in brain function because the brain undergoes significant 
developmental changes at this age (Choudhury et al, 2006). Hippocampal hypertrophy has been 
associated with adolescent cannabis use (mean age 17 years, mean exposure duration two years) 
(Medina  et al., 2007), although this was not found by Gilman, et al. (2014). Findings of 
increased grey matter density in other limbic subcortical structures in young cannabis users may 
reflect cannabis-induced changes in arborisation (Gilman et al., 2014). In parallel, there is some 
evidence of a relationship between prefrontal volume and executive dysfunction in adolescent 
users (Medina et al., 2009).  These structural findings were extended by a study (Ashtari et al., 
2009) of young male heavy cannabis users who, compared to non-users, had reduced 
frontotemporal structural connectivity via the arcuate fasciculus. Importantly, there is 
longitudinal evidence of structural hypoconnectivity associated with cannabis use in adolescents 
(Epstein & Kumra, 2015). In terms of functional connectivity, a large study (Thijssen et al., 
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2017) in adolescents found a relationship between duration of cannabis use and reduced 
functional connectivity within the default mode, executive control and auditory networks. In a 
study of adolescents admitted for treatment of cannabis dependence, the level of dependence was 
associated with reduced interhemispheric yet increased right intrahemispheric resting functional 
connectivity (Orr et al., 2013).  Some studies have investigated the functional significance of 
dysconnectivity.  For example, in young male long-term heavy cannabis users, drug use was 
associated with reduced striato-frontal connectivity (Blanco-Hinojo et al., 2017). These 
connectivity alterations were associated with lower arousal in response to affective pictures as 
measured with the International Affective Picture System and normalized after abstinence. A 
separate, longitudinal study of resting functional connectivity in adolescents demonstrated 
dysconnectivity between the caudal ACC, dorsolateral and orbitofrontal cortices over an 18 
month follow-up period (Camchong et al., 2017). Amounts of cannabis use during this period 
were associated with inattention and impaired cognition. Another study found greater bilateral 
amygdalar activity during emotional processing, rather than the reduction seen in adults, to angry 
faces rather than neutral faces in 70 adolescent cannabis users (Spechler et al., 2015). However, 
this may simply be because the adolescent participants in Spechler’s sample had very minimal 
exposure in comparison to studies of heavy adult users. These studies suggest that adolescence 
may be a particularly critical time for cannabis’ effects on emotional and cognitive function. 
These findings are in keeping with a recent literature review suggesting that early, heavy 
cannabis use in adolescence predicts poor emotional processing and cognition in adulthood 
(Levine et al., 2017).  
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However, the significance of these neuroimaging findings relative to cognitive 
performance is unclear. A systematic review in 2016 found that whilst adolescent heavy cannabis 
users have radiological evidence of dysconnectivity, their performance in cognitive tasks is 
similar to controls (Lorenzetti et al., 2016a). This led the authors to question whether functional 
dysconnectivity in these adolescents is caused by cannabis use, or is an adaptation that affords 
normal cognitive functioning.  Further longitudinal studies are needed to clarify the significance 
of cannabis use in adolescence on cognition (James et al., 2013). Moreover, experimental, 
placebo-controlled studies are warranted. The only study to date (Mokrysz et al., 2016) found 
that adolescent cannabis users showed a profile characterised by resilience to some acute effects 
of cannabis (memory impairment, psychotic-like symptoms) and vulnerability to others (lack of 
satiety, impaired inhibitory processing). 
 
Cognitive task performance may alter with abstinence (Scott et al., 2018).  Abstinent 
adolescent cannabis users showed left orbitofrontal hypoactivation to non-reward vs. risky 
rewards which was related to cannabis use duration (De Bellis et al., 2013) whereas a separate 
study found evidence of fronto-parietal hyperactivation during response inhibition (Tapert et al., 
2007). Whilst causal inferences are limited, these findings would be in keeping with increased 
incentive salience toward riskier rewards alongside less efficient response inhibition – which 
may be related to addictions generally and not specifically cannabis use.  
 
There is consistent preclinical and neuropsychological evidence for cognitive effects of 
cannabis use during adolescence (Jager & Ramsey, 2008; Schweinsburg et al., 2008). 
Adolescents exhibit a similar pattern to adults of task performance and brain activity associated 
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with non-acute cannabis effects (Bossong et al., 2014). Adolescent cannabis use is associated 
with increases in brain activity in prefrontal and parietal brain areas (Jacobsen et al., 2007; Jager 
et al., 2010; Schweinsburg et al., 2008; Schweinsburg et al., 2010) which may reflect reduced 
cortical efficiency. Adolescent cannabis use is also associated with greater task-induced de-
activation (Schweinsburg et al., 2008; Schweinsburg et al., 2005; Schweinsburg et al., 2010) 
which is consistent with increased effort to maintain task performance. Comparisons between 
adult and adolescent studies are limited by lower cumulative exposure, lower duration of 
exposure in adolescents than in adults alongside differences in durations of abstinence. 
Nonetheless, it remains possible that the effects of cannabis use on the adolescent brain may be 
more harmful given the potential to alter developmental trajectories (Bossong & Niesink, 2010; 
Curran et al., 2016).  
  
6.  Cannabis use disorders 
 
Based on population-based data from the United States in 2012-2013, the past year 
prevalence of cannabis use disorders was estimated at 2.9%, or 30.6% among past-year users 
(Hasin et al., 2015).  Given the high rate of cannabis use worldwide, estimated at 183 million 
past year users (UNODC, 2018), a substantial number of people currently meet criteria or at risk 
of developing a cannabis use disorder. In terms of clinical implications, cannabis now accounts 
for around half of all first-time entrants to specialist drug treatment worldwide (UNODC, 2018) 
and has now superseded opiates as the primary reason for first-time treatment entry of all illicit 
drugs in Europe (EMCDDA, 2018). One possible contributor to the increase in cannabis-related 
treatment admissions may be the increase potency of cannabis products, resulting in a higher 
dose of THC and greater harm to users. A 16-year study in the Netherlands found that changes in 
ACCEPTED MANUSCRIPT
AC
CE
PT
ED
 M
AN
US
CR
IPT
 
the THC concentration of cannabis sold in national retail outlets were positively associated with 
the number of people subsequently entering treatment for cannabis problems (Freeman et al., 
2018b). Psychological interventions such as Cognitive Behavioural Therapy and Motivational 
Interviewing have limited effectiveness, and there are no approved pharmacotherapies available. 
  
The high density of CB1Rs in reward and habit circuits, and the key role of the 
endocannabinoid system in reinforcement may underpin the effects of THC in the development, 
withdrawal and relapse of cannabis use disorders (Curran, et al., 2016). Chronic THC exposure 
is associated with downregulation of CB1Rs (Ceccarini et al., 2015; D'Souza et al., 2016; 
Hirvonen et al., 2012). Moreover, withdrawal from chronic cannabis administration is associated 
with reduced dopamine transmission in the NAc (Diana et al., 1998) and the reduction in striatal 
dopamine synthesis capacity shown found in cannabis users was driven by those meeting clinical 
Diagnostic & Statistic Manual of Mental Disorders IV criteria for cannabis use disorders 
(Bloomfield et al., 2014a). Evidence for blunting of the dopamine system in cannabis use 
disorders (Bloomfield et al., 2016) is consistent with prospective evidence from a longitudinal 
analysis of adults aged 20, 22, and 24 (Martz et al., 2016). That study found that cannabis use 
predicted a blunted NAc response to reward anticipation at subsequent time points. If cannabis 
use dampens anticipatory reward processing over time, as suggested by this study, chronic use 
may increase vulnerability to mental health disorders across diagnostic categories including 
addiction to other substances and gambling (Luijten et al., 2017) depression and psychosis 
(Hagele et al., 2015). 
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7. Cannabis and psychoss  
 
  When considering the links between cannabis use and psychosis it is important to 
remember that the schizophreniform clinical syndrome lies at a confluence of phenotypes 
including hallucinations, paranoia, amotivation and cognitive impairment.  All of these have 
been associated with acute exposure to THC (Bhattacharyya et al., 2010; Broyd et al., 2016; 
Curran et al., 2016; D'Souza et al., 2004; Moreau, 1845; Morrison & Stone, 2011; Morrison et 
al., 2009) and long-term heavy cannabis use (Broyd et al., 2016; Curran et al., 2016; Freeman et 
al., 2013; Marconi et al., 2016) in vulnerable individuals. Cannabis produces complex 
neuropharmacological effects on systems underlying these experiences.  There are several 
important findings that stand out which relate to executive function, memory and the limbic 
system.  For example, THC alters the neural response during working memory performance 
(Bocker et al., 2010; Bossong et al., 2012)) as seen in schizophrenia (Sutcliffe et al., 2016).  
Likewise, psychosis is associated with altered threat processing (Freeman et al., 2013) and THC 
produces complex effects on neural systems underlying fear processing including altered 
amygdalar response to threat and reduced amygdalo-cortical coupling (Gorka et al., 2015), and 
THC may be anxiogenic via non-amygdalar pathways.  Recent work has shown that CB1Rs are 
involved in midbrain threat processing (Back & Carobrez, 2018) and further work is needed to 
understand the potential involvement of these pathways in the pathophysiology of psychosis.  
Structurally, changes associated with early onset heavy use include hippocampal (Rocchetti et 
al., 2013) and amygdalar atrophy (Lorenzetti et al., 2015) alongside aberrant self-processing and 
executive network connectivity (Cheng et al., 2014; Filbey & Dunlop, 2014; Lopez-Larson et al., 
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2015; Orr et al., 2016), which map conceptually onto schizophreniform symptomatology.  At the 
molecular level, heavy cannabis use is associated with perturbations of the endocannabinoid 
system (D'Souza et al., 2016). The development of clinical schizophrenia following heavy use 
may be through non-hyperdopaminergic processes (Bloomfield et al., 2016) in contrast to 
idiopathic schizophrenia (Howes & Kapur, 2014), with potential candidate mechanisms 
including excitatory-inhibitory imbalance between GABA-ergic (Radhakrishnan et al., 2015) 
and glutamatergic (Prescot et al., 2013) systems, which are intimately modulated by the 
endocannabinoid system.  Together these neurocognitive, neurochemical and structural changes 
could therefore give rise to clinical schizophrenia in people who are vulnerable to the deleterious 
effects of cannabis use across the dimensions of the clinical syndrome.  
  
Broadly speaking there are two possible explanations for this which are not mutually 
exclusive: (1) cannabis is exacerbating the same vulnerabilities that cause idiopathic 
schizophrenia and (2) cannabis causes additional routes to the phenotype. One of the first 
neuroimaging studies in cannabis and psychosis used CT (Wiesbeck & Taeschner, 1991) to 
compare a drug-using group of patients with psychotic symptoms to a non-using group of 
patients found no differences between the two groups. Subsequently, Cunha et al. (2013) found 
that cannabis using patients with first episode psychosis did not have grey matter volume deficits 
in the medial temporal lobe or PFC that were typical of psychotic patients without cannabis use 
suggesting that cannabis use induced psychosis via different neurodevelopmental pathways to 
idiopathic schizophrenia. In support of this, a small study (Dragogna et al., 2014) found that 
patients with cannabis-induced psychosis had hypermetabolism in the posterior cingulate and 
precuneus compared to patients with schizophrenia without cannabis use. In a study comparing 
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white matter connectivity in adolescent-onset schizophrenia with and without cannabis use (over 
three times per week for at least six months) there was decreased fractional anisotropy in the 
internal capsule, corona radiata, superior and inferior longitudinal fasciculus (James et al., 2011). 
However, a previous study limited by small sample size (Peters et al., 2009) found contrary 
evidence. THC-induced effects have been extended to functional connectivity in patients with 
schizophrenia and co-morbid cannabis use disorder, assessed after seven days of abstinence 
(Fischer et al., 2014). At baseline, patients in this study had hypoconnectivity between the NAc 
and frontal reward regions including the OFC and ACC, which was reversed upon THC 
challenge. One possible explanation is that patients with schizophrenia may be motivated to use 
cannabis in order to restore their dysregulated brain reward circuitry. In addition, in a study of 
adolescents with early onset schizophrenia (Epstein et al., 2014), cannabis use was associated 
with impaired attention network function compared to patients without cannabis use disorder. 
Atakan and colleagues (2013) compared brain function between subjects who did (N=11) and 
did not (N=10) experience psychotic effects following oral THC administration (10 mg). THC 
showed stronger effects on inhibition errors in the group of participants with psychotic 
symptoms, accompanied by increased psychosis-related activity in the right middle temporal 
gyrus and decreased activity in the parahippocampal and fusiform gyri. Following this, a large 
study of patients at clinical high risk of schizophrenia (Buchy et al., 2015) examined the 
relationship between thalamic dysconnectivity and cannabis use.  Whilst there was no discernible 
effects on thalamic connectivity based on current cannabis use status, there was some evidence 
that within patients at high clinical risk of schizophrenia who were also cannabis users, there was 
a relationship between thalamo-sensorimotor hypoconnectivity and age of onset of cannabis use. 
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Findings of differences between patients with psychosis with and without cannabis use 
(Cunha et al., 2013; Dragogna et al., 2014; James et al., 2011) may support the presence of a 
potentially distinct ecophenotypic subtype of schizophrenia secondary to heavy cannabis use 
which could have implications for prevention and treatment thereby necessitating further work to 
investigate how these differences relate to phenomenology on the one hand.  On the other hand, 
understanding shared mechanisms has the potential to yield new treatment targets - which would 
be most welcome for a disorder which has seen minimal progress in meaningful new treatments 
since Kane’s pioneering work on clozapine 30 years ago (Kane et al., 1988).   
 
8. Discussion 
  
The large body of work reviewed indicates that cannabis can alter brain structure, 
interfere with executive function, subvert the reward system, and produce complex effects on 
emotional processing.  A wide range of neuropharmacological systems likely underlie these 
effects including the endocannabinoid, dopamine, glutamate and GABA systems. The mounting 
evidence is testament to the importance and broad interest in the topic over the last few decades. 
The imaging methods used (from early volumetric CT studies, to contemporary functional 
imaging) are diverse, and many of the methods themselves have been undergoing significant 
development in the same time period. Beyond the experimental methods, the literature is 
extremely varied in a number of other factors including the participant population studied, route 
of administration and dose used (for acute challenge studies), and the definitions of usage (for 
studies of chronic users). All these factors present challenges to the construction of a coherent 
synthesis. Nonetheless, we have presented a number of themes and a set of relatively consistent 
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results that we have seen emerge. We will now describe some of the methodological 
considerations that limit the interpretations that we have made from this field of research.   
  
Pharmacological Considerations 
 
There are a range of factors that may account for disparities in the results between 
studies.  Firstly, in some experiments participants were given cannabis, whereas in other studies 
pure THC was administered. Although THC is the main psychoactive ingredient, cannabis 
contains at least 144 phytocannabinoids (Hanuš et al., 2016), and therefore the acute effects of 
THC and cannabis are likely to be different. Secondly, studies applied different methods of 
administration with varying doses of THC, resulting in different pharmacokinetic and 
pharmacodynamic effects (Grotenhermen, 2003). Thirdly, oral consumption generally leads to 
slower absorption and lower bioavailability of THC, and a delay in the onset of acute 
behavioural effects compared to inhalation (Agurell et al., 1986; Grotenhermen, 2003). Finally, 
variation in the participants’ history of cannabis use between studies may have affected the 
findings, as frequent cannabis use may result in blunted responses to acute effects of cannabis 
(Curran et al., 2018; D'Souza et al., 2008). For studies on the chronic effects of cannabis, 
interpretation of the results is significantly hampered by large differences in characteristics of 
study populations. These include frequency, quantity, history and age of onset of cannabis use, 
time that subjects were abstinent from using cannabis, and rates of tobacco smoking, alcohol 
consumption and use of other illicit drugs. For the studies on the chronic effects of cannabis, 
differences in the composition of cannabis may also be important. The effects of cannabis appear 
to depend on the ratio between THC and CBD as both substances may have opposite neural 
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effects during fMRI (Bhattacharyy et al., 2012; Bhattacharyya et al., 2010).  Therefore, the 
composition of cannabis may have been a confounding factor when investigating non-acute 
effects of cannabis. The composition of cannabis has also changed over time (ElSohly et al., 
2016; Pijlman et al., 2005; Potter et al., 2018; Zameng, et al., 2015) which may have affected the 
comparison of findings between studies as well as individual results within studies. Furthermore, 
definitions of what constitutes a “cannabis user” are highly inconsistent across studies and 
alongside this, consensus is needed in the field as to how to measure the amount of 
cannabis/THC being consumed i.e. an internationally agreed standard unit of THC and 
THC:CBD ratio for users, clinicians and scientists (Hindocha et al., 2018b).  Lastly, there is the 
perennial challenge of retrospective recall of the amount of cannabis that is being consumed 
which can only be addressed through robust prospective designs.   
 
Imaging Considerations 
 
The imaging methods used are diverse and range from early studies looking at volumetric 
measures with CT images, PET studies with various ligands, diffusion MRI, functional MRI, and 
even some EEG studies. Each of these methods has their own set of advantages and drawbacks 
that are generally relatively well-known and adequately described elsewhere. We will, therefore, 
focus on specific idiosyncrasies that apply to the literature reviewed above.  
 
There is an emerging awareness that many neuroscience studies may be severely under-
powered in a statistical sense (Button et al., 2013; Nord et al., 2017) and neuroimaging studies 
may be particular examples, because their relatively high cost (in both money, and researcher 
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time) make collecting large samples difficult. Under-powered studies can produce false positive 
results (the “winner’s curse” effect; Button et al., 2013) that subsequently fail to replicate 
(Cremers et al., 2017) and over time this potentially leads to a large number of inconsistent 
results, and low reproducibility in the literature as a whole. Low power may be a particular issue 
in pharmacological neuroimaging research as many studies use between-subjects designs (e.g. 
comparing cannabis users and non-users), or within-subjects designs where the relevant 
comparisons are on different days and/or scan sessions (e.g. comparing placebo and active 
cannabis), sometimes weeks apart. Both of these designs inherently have higher noise levels (and 
therefore lower power) than a more ‘standard’ neuroimaging experimental design where, for 
example, active task and rest conditions are compared within a single scan session. In addition, 
neuroimaging is a rapidly evolving field, with major advancements continuing to be made in 
both acquisition (hardware and software) and analysis methods. These innovations mean that the 
acquisition and analysis procedures in methods such as fMRI are not fully standardised, and may 
not be for the foreseeable future. For example, in early fMRI studies it was relatively common to 
use uncorrected thresholds of p < 0.001 in group-level analyses (e.g. Kanayama, et al., 2004) but 
this would be deemed unacceptably lax in most modern studies. Recent high-profile work has 
highlighted somewhat more subtle, but important, statistical issues (Eklund et al., 2016) which 
may also contribute to the production of false-positive results in the literature. There is little 
practical utility in an exercise of formally re-assessing large sections of the literature in light of 
these advancements, however the enlightened reader should certainly bear these issues in mind 
when evaluating previous work, particularly the older studies, with relatively small numbers of 
subjects.  
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The methods continue to advance, and recent innovations such as lightweight, wireless 
EEG systems (Ratti et al., 2017), high field-strength MRI scanners (Duyn, 2012) highly 
accelerated scanning sequences for fMRI (Demetriou et al., 2018), machine-learning based 
analysis methods (Doyle et al., 2015) and combined PET/MR scanners (Sauter et al., 2010) are 
of great interest, but will also necessarily entail their own sets of caveats and compromises. 
Larger-scale publically-available data sets with many hundreds of subjects such as the Human 
Connectome Project (HCP; e.g. Pagliaccio, et al., 2015) and the UK Biobank (Sudlow et al., 
2015) are also beginning to address the issues of small sample sizes and low experimental power. 
True standardisation of methods in human neuroimaging is unlikely while the field is undergoing 
such rapid and continuous advancement, but attempts to unite around common standards for at 
least some aspects of the procedures are making some headway (e.g. Esteban et al., 2018). All 
these developments are highly positive, and can only lead to higher-quality, more robust, and 
more reproducible future work.  
 
The future  
 Great progress has been made in our understanding of the effects of cannabis and THC 
on the human brain. This progress will likely intensify, given the public health implications of 
heavy use, changes to the legal landscape of the drug and new medicines in the pipeline that will 
target the endocannabinoid system.  Given the changing patterns of use, with heavy use 
appearing to carry the most risk, there is an urgent need to fully elucidate the effects of heavy 
cannabis use during development and their reversibility.  Beyond THC, we must understand the 
diverse effects of the myriad of phytocannabinoids in cannabis and the synthetic cannabinoids 
that are being increasingly used recreationally.  Likewise, we must reach a precise understanding 
of the neurobiological mechanisms underlying cannabis dependence and psychosis. This should 
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include systematic multimodal imaging that can better update our understanding of such complex 
mechanisms than single neuroimaging methods. In parallel, greater understanding of these 
systems may offer hope to the many millions of people suffering from mental illnesses 
throughout the world in the form of new treatments.    
  
9. Conclusions 
 
There is a mounting body of evidence informing us of both the mechanisms underlying 
the psychoactive effects of THC and the long-term effects of cannabis use. The available 
evidence suggests the drug disrupts emotional processes, executive function and reward function 
via the endocannabinoid system which likely underlie the mental health problems associated 
with heavy cannabis use. While also informing the underlying pathophysiology of a range of 
disorders, improved understanding of these systems may lead to new treatment targets in the 
future.  Both longitudinal studies and well-designed pharmacological challenges are needed to 
elucidate the precise effects of THC, CBD and the other major cannabinoids on the brain.   
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